<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">53278</article-id><article-id pub-id-type="doi">10.7554/eLife.53278</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title><italic>GATA6</italic> mutations in hiPSCs inform mechanisms for maldevelopment of the heart, pancreas, and diaphragm</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-165369"><name><surname>Sharma</surname><given-names>Arun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0607-5455</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-165370"><name><surname>Wasson</surname><given-names>Lauren K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5193-5215</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165371"><name><surname>Willcox</surname><given-names>Jon AL</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165372"><name><surname>Morton</surname><given-names>Sarah U</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165373"><name><surname>Gorham</surname><given-names>Joshua M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165374"><name><surname>DeLaughter</surname><given-names>Daniel M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165375"><name><surname>Neyazi</surname><given-names>Meraj</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165376"><name><surname>Schmid</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165377"><name><surname>Agarwal</surname><given-names>Radhika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165378"><name><surname>Jang</surname><given-names>Min Young</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165379"><name><surname>Toepfer</surname><given-names>Christopher N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165380"><name><surname>Ward</surname><given-names>Tarsha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165381"><name><surname>Kim</surname><given-names>Yuri</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-164055"><name><surname>Pereira</surname><given-names>Alexandre C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165382"><name><surname>DePalma</surname><given-names>Steven R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165383"><name><surname>Tai</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165384"><name><surname>Kim</surname><given-names>Seongwon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165385"><name><surname>Conner</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165386"><name><surname>Bernstein</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165387"><name><surname>Gelb</surname><given-names>Bruce D</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165388"><name><surname>Chung</surname><given-names>Wendy K</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165389"><name><surname>Goldmuntz</surname><given-names>Elizabeth</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2936-4396</contrib-id><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165390"><name><surname>Porter</surname><given-names>George</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165391"><name><surname>Tristani-Firouzi</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-159056"><name><surname>Srivastava</surname><given-names>Deepak</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3480-5953</contrib-id><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-80222"><name><surname>Seidman</surname><given-names>Jonathan G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9082-3566</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-78102"><name><surname>Seidman</surname><given-names>Christine E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6380-1209</contrib-id><email>cseidman@genetics.med.harvard.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con27"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>Pediatric Cardiac Genomics Consortium</collab><xref ref-type="fn" rid="con28"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Genetics, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Smidt Heart Institute, Cedars-Sinai Medical Center</institution><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center</institution><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Howard Hughes Medical Institute, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Division of Newborn Medicine, Boston Children's Hospital</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Hannover Medical School</institution><addr-line><named-content content-type="city">Hannover</named-content></addr-line><country>Germany</country></aff><aff id="aff7"><label>7</label><institution>Deutsches Herzzentrum München, Technische Universität München</institution><addr-line><named-content content-type="city">Munich</named-content></addr-line><country>Germany</country></aff><aff id="aff8"><label>8</label><institution>Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff9"><label>9</label><institution>Wellcome Centre for Human Genetics, University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff10"><label>10</label><institution>Laboratory of Genetics and Molecular Cardiology, Heart Institute, Medical School of University of Sao Paulo</institution><addr-line><named-content content-type="city">Sao Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff11"><label>11</label><institution>Department of Pediatrics, Stanford University School of Medicine</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution>Department of Medicine, Columbia University Medical Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff14"><label>14</label><institution>Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff15"><label>15</label><institution>Department of Pediatrics, University of Rochester Medical Center</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff><aff id="aff16"><label>16</label><institution>Division of Pediatric Cardiology, University of Utah School of Medicine</institution><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff17"><label>17</label><institution>Gladstone Institutes</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff18"><label>18</label><institution>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Morrisey</surname><given-names>Edward E</given-names></name><role>Reviewing Editor</role><aff><institution>University of Pennsylvania</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Morrisey</surname><given-names>Edward E</given-names></name><role>Senior Editor</role><aff><institution>University of Pennsylvania</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e53278</elocation-id><history><date date-type="received" iso-8601-date="2019-11-01"><day>01</day><month>11</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-10-14"><day>14</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Sharma et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Sharma et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-53278-v2.pdf"/><abstract><p>Damaging <italic>GATA6</italic> variants cause cardiac outflow tract defects, sometimes with pancreatic and diaphragmic malformations. To define molecular mechanisms for these diverse developmental defects, we studied transcriptional and epigenetic responses to <italic>GATA6</italic> loss of function (LoF) and missense variants during cardiomyocyte differentiation of isogenic human induced pluripotent stem cells. We show that GATA6 is a pioneer factor in cardiac development, regulating <italic>SMYD1</italic> that activates <italic>HAND2,</italic> and <italic>KDR</italic> that with <italic>HAND2</italic> orchestrates outflow tract formation. LoF variants perturbed cardiac genes and also endoderm lineage genes that direct <italic>PDX1</italic> expression and pancreatic development. Remarkably, an exon 4 <italic>GATA6</italic> missense variant, highly associated with extra-cardiac malformations, caused ectopic pioneer activities, profoundly diminishing <italic>GATA4</italic>, <italic>FOXA1/2,</italic> and <italic>PDX1</italic> expression and increasing normal retinoic acid signaling that promotes diaphragm development. These aberrant epigenetic and transcriptional signatures illuminate the molecular mechanisms for cardiovascular malformations, pancreas and diaphragm dysgenesis that arise in patients with distinct <italic>GATA6</italic> variants.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>stem cells</kwd><kwd>iPSC</kwd><kwd>gene mutation</kwd><kwd>CRISPR</kwd><kwd>heart</kwd><kwd>development</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>UM1HL128711</award-id><principal-award-recipient><name><surname>Porter</surname><given-names>George</given-names></name><name><surname>Tristani-Firouzi</surname><given-names>Martin</given-names></name><name><surname>Srivastava</surname><given-names>Deepak</given-names></name><name><surname>Seidman</surname><given-names>Jonathan G</given-names></name><name><surname>Seidman</surname><given-names>Christine E</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>UM1HL128761</award-id><principal-award-recipient><name><surname>Seidman</surname><given-names>Christine E</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>UM1HL098147</award-id><principal-award-recipient><name><surname>DeLaughter</surname><given-names>Daniel M</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U01-HL098153</award-id><principal-award-recipient><name><surname>Seidman</surname><given-names>Jonathan G</given-names></name><name><surname>Seidman</surname><given-names>Christine E</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U01-HL098163</award-id><principal-award-recipient><name><surname>Seidman</surname><given-names>Jonathan G</given-names></name><name><surname>Seidman</surname><given-names>Christine E</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U01-HL098123</award-id><principal-award-recipient><name><surname>Seidman</surname><given-names>Jonathan G</given-names></name><name><surname>Seidman</surname><given-names>Christine E</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U01-HL098162</award-id><principal-award-recipient><name><surname>Seidman</surname><given-names>Jonathan G</given-names></name><name><surname>Seidman</surname><given-names>Christine E</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>EEC-1647837</award-id><principal-award-recipient><name><surname>Seidman</surname><given-names>Jonathan G</given-names></name><name><surname>Seidman</surname><given-names>Christine E</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32HL116273</award-id><principal-award-recipient><name><surname>Sharma</surname><given-names>Arun</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wasson</surname><given-names>Lauren K</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Analyses of human stem cells with distinct <italic>GATA6</italic> mutations revealed a spectrum of molecular responses that drive isolated congenital heart disease or the co-occurrence of pancreas and diaphragm malformations.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Congenital heart disease (CHD), the leading birth defect worldwide that occurs in approximately 1% of newborns (<xref ref-type="bibr" rid="bib80">van der Linde et al., 2011</xref>), comprises a range of structural malformations arising during embryonic development (<xref ref-type="bibr" rid="bib86">Zaidi and Brueckner, 2017</xref>). Contemporary treatments for CHD enables survival into adulthood, but many patients have ongoing medical problems related to extra-cardiac malformations and/or neurodevelopmental disabilities (<xref ref-type="bibr" rid="bib7">Brickner et al., 2000</xref>; <xref ref-type="bibr" rid="bib58">Marino et al., 2012</xref>). Understanding the developmental mechanisms that cause co-occurrence of these congenital anomalies is expected to provide better patient care, improve predictive risk assessments, and potentially uncover therapeutic targets.</p><p>Heart development is an intricately regulated process driven by genetic, epigenetic, and biomechanical events that form a complex, multi-chambered, muscular organ containing cardiomyocytes and other cell lineages (<xref ref-type="bibr" rid="bib50">Litviňuková et al., 2020</xref>). Early in cardiogenesis, the first heart field creates the left ventricle and portions of the atria, while the second heart field gives rise to the right ventricle and outflow tract, with contributions from neural crest cells (<xref ref-type="bibr" rid="bib9">Buckingham et al., 2005</xref>). Multiple transcription factors orchestrate particular components of these developmental processes (<xref ref-type="bibr" rid="bib73">Srivastava and Olson, 2000</xref>), as evidenced by regional defects in CHD patients with damaging mutations in particular genes (<xref ref-type="bibr" rid="bib22">Fahed et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Jin et al., 2017</xref>; <xref ref-type="bibr" rid="bib71">Sifrim et al., 2016</xref>). For example, dominant human loss of function (LoF) variants in <italic>TBX5</italic>, <italic>NKX2</italic>-5, and <italic>GATA4</italic> that are highly expressed in the first and second heart fields cause atrial and ventricular septal defects (<xref ref-type="bibr" rid="bib3">Basson et al., 1997</xref>; <xref ref-type="bibr" rid="bib5">Benson et al., 1999</xref>; <xref ref-type="bibr" rid="bib25">Garg et al., 2003</xref>). <italic>GATA6</italic>, while expressed in the first heart field (<xref ref-type="bibr" rid="bib62">Morrisey et al., 1996</xref>), plays particularly critical roles in the developing second heart field (<xref ref-type="bibr" rid="bib61">Molkentin, 2000</xref>) and in recruitment of cardiac neural crest lineages (<xref ref-type="bibr" rid="bib46">Lepore et al., 2006</xref>) that together shape the cardiac outflow tract. Consistent with these developmental functions, CHD patients with <italic>GATA6</italic> mutations have a striking preponderance of outflow tract malformations (<xref ref-type="bibr" rid="bib28">Gharibeh et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Kodo et al., 2009</xref>; <xref ref-type="bibr" rid="bib56">Maitra et al., 2010</xref>). <italic>GATA6</italic> also is critical for endodermal development (<xref ref-type="bibr" rid="bib23">Fisher et al., 2017</xref>), and some CHD patients with damaging <italic>GATA6</italic> variants also have pancreatic agenesis, congenital diaphragmatic hernia (<xref ref-type="bibr" rid="bib83">Yu et al., 2014</xref>) or other abdominal malformations (<xref ref-type="bibr" rid="bib12">Chao et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">De Franco et al., 2013</xref>; <xref ref-type="bibr" rid="bib70">Shi et al., 2017</xref>).</p><p>Developmental transcription factors work in concert to exert network-level effects on organogenesis (<xref ref-type="bibr" rid="bib53">Luna-Zurita et al., 2016</xref>): physical interactions of NKX2-5, TBX5, and GATA4 proteins modulate the expression of other cardiac genes (<xref ref-type="bibr" rid="bib25">Garg et al., 2003</xref>; <xref ref-type="bibr" rid="bib32">Hiroi et al., 2001</xref>; <xref ref-type="bibr" rid="bib8">Bruneau et al., 2001</xref>; <xref ref-type="bibr" rid="bib55">Maitra et al., 2009</xref>) while GATA6 and GATA4 proteins together promote pancreatic development (<xref ref-type="bibr" rid="bib12">Chao et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">De Franco et al., 2013</xref>; <xref ref-type="bibr" rid="bib70">Shi et al., 2017</xref>). Notably, members of the GATA family of transcription factors serve as endodermal pioneer factors that participate with FOXA, also a pioneer factor, to engage and open chromatin and recruit additional transcriptional activators (<xref ref-type="bibr" rid="bib23">Fisher et al., 2017</xref>; <xref ref-type="bibr" rid="bib87">Zaret and Carroll, 2011</xref>). Thus, we expect that understanding the molecular networks in which <italic>GATA6</italic> participates will help to elucidate the mechanisms by which human mutations cause defects in morphogenesis of the heart cardiac other organs.</p><p>A traditional approach for studying developmental mechanisms relies on gene disruption in model organisms. While often informative, prior studies of mice with one inactivated <italic>Gata6</italic> allele have either subtle dysmorphic aortic valves (<xref ref-type="bibr" rid="bib28">Gharibeh et al., 2018</xref>) or no CHD (<xref ref-type="bibr" rid="bib46">Lepore et al., 2006</xref>) and notably lack pancreatic agenesis or congenital diaphragmatic hernia that occur in human CHD patients with damaging <italic>GATA6</italic> variants (<xref ref-type="bibr" rid="bib12">Chao et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">De Franco et al., 2013</xref>; <xref ref-type="bibr" rid="bib70">Shi et al., 2017</xref>). Mice with biallelic <italic>Gata6</italic> inactivation have deficits in early visceral endoderm formation resulting in nonviable embryos (<xref ref-type="bibr" rid="bib62">Morrisey et al., 1996</xref>; <xref ref-type="bibr" rid="bib89">Zhao et al., 2005</xref>), which may explain the absence of homozygous <italic>GATA6</italic> null alleles in humans, but provide limited insights into organ morphogenesis. The introduction of human CHD mutations using CRISPR/Cas9 (<xref ref-type="bibr" rid="bib18">De Franco et al., 2013</xref>) into isogenic human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provides an alternative model system suited for analyzing developmental consequences, as differentiation of these cells activate transcriptional networks that regulate early in vivo human cardiogenesis (<xref ref-type="bibr" rid="bib19">DeLaughter et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Li et al., 2016</xref>). Moreover, isogenic hiPSC-CMs containing distinct variants can illuminate variant-specific transcriptional patterns.</p><p>We employed this approach to study human de novo GATA6 variants, identified by whole-exome sequencing (WES) of CHD patients. We demonstrate the graded transcriptional effects of <italic>GATA6</italic> heterozygous and homozygous LoF variants during hiPSC-CM differentiation. We also examine the transcriptional requirements for a specific arginine residue encoded by <italic>GATA6</italic> exon four that is recurrently mutated in unrelated CHD patients. Combining these data with Assay for transposase-accessible chromatin using sequencing (ATAC-seq) (<xref ref-type="bibr" rid="bib10">Buenrostro et al., 2015</xref>; <xref ref-type="bibr" rid="bib17">Corces et al., 2017</xref>) and GATA6 ChIP-seq analyses, we demonstrate that GATA6 is a pioneer factor for cardiac development. We define direct and indirect transcriptional responses to <italic>GATA6</italic> variants. Integrating these datasets with clinical phenotypes observed in CHD patients with pathogenic <italic>GATA6</italic> variants, we demonstrate how disrupted molecular programs cause aberrant development of the cardiac outflow tract, pancreas, and diaphragm.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Identification of CHD patients with <italic>GATA6</italic> LoF and missense variants</title><p>Among &gt;4000 CHD patients enrolled and studied by WES through National Heart, Lung, and Blood Institute’s Pediatric Cardiac Genomics Consortium (PCGC) (<xref ref-type="bibr" rid="bib33">Homsy et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Jin et al., 2017</xref>), we identified nine heterozygous de novo variants: four LoF (LoF) and five damaging missense variants in <italic>GATA6</italic> (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The congenital anomalies in these patients were consistent with previously recognized roles for <italic>GATA6</italic> in developing the cardiac outflow tract, arterial-ventricular valves, and posterior brachial arches that form aorta and pulmonary vessels (<xref ref-type="bibr" rid="bib28">Gharibeh et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Laforest and Nemer, 2011</xref>; <xref ref-type="bibr" rid="bib51">Losa et al., 2017</xref>). Among PCGC CHD patients and 61 previously reported CHD patients with pathogenic <italic>GATA6</italic> variants (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) there were a preponderance of outflow tract malformations, including persistent truncus arteriosus, double-outlet right ventricle, tetralogy of Fallot, as well as aortic and pulmonary valve and septation defects (<xref ref-type="bibr" rid="bib40">Kelly, 2012</xref>). Some but not all of these patients also had extra-cardiac phenotypes including pancreatic agenesis, congenital diaphragmatic hernia, and neurodevelopmental deficits.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Genetic information and clinical phenotypes of individuals with <italic>GATA6</italic> variants.</title><p><bold>A</bold>) Schematic of <italic>GATA6</italic> gene and locations of PCGC <italic>GATA6</italic> variants (LoF-purple, missense-orange). (<bold>B</bold>) Previously described (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) <italic>GATA6</italic> variants (R456 and N466 variants highlighted in red), and GATA6 protein domains. TAD: Topologically associating domain, ZF: zinc finger, NLS: nuclear localization signal. TGA: Transposition of the Great Arteries, ToF: Tetralogy of Fallot, DORV: Double-Outlet Right Ventricle, DOLV: Double-Outlet Left Ventricle, DXC: Dextrocardia, VSD: Ventricular Septal Defect, HLV: Hypoplastic Left Ventricle, PA: Pulmonary Atresia, ASD: Atrial Septal Defect, PTA: Persistent Truncus Arteriosus, SPS: Supravalvular Pulmonary Stenosis, HLPA: Hypoplastic Left Pulmonary Artery, PS: Pulmonary Stenosis, HPA: Hypoplastic Pulmonary Artery, PANC: Pancreatic Agenesis (<bold>C</bold>) Model of GATA6 DNA-binding domain bound to major groove of DNA indicating the location of amino acid residue 456. Left panel: GATA6 residues R456 and N466 normally interact with each other via hydrogen bonding (dashed lines) and with target G base and second A base in the GATA motif via hydrogen bonding, respectively (dashed lines). Right panel: Replacing the arginine (R) residue at position 456 with a glycine (G) residue alters normal molecular interactions by disrupting the hydrogen bonds.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig1-v2.tif"/></fig><p>We considered whether the distribution of these 70 damaging <italic>GATA6</italic> variants (61 published, 9 PCGC) across the 595 encoded GATA6 amino acids correlated with clinical phenotypes (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1A, B</xref>). All variants (43 missense, 27 LoF, including eight recurrent variants) caused CHD. Extra-cardiac phenotypes occurred in 29/70 (41%) patients, and more often with LoF (18/27) than missense (11/43) variants (p&lt;0.001). Neurocognitive dysfunction occurred in 13 patients (18.5%). Pancreatic agenesis/hypoplasia or congenital diaphragmatic hernia occurred in 20/70 patients (28.5%) and more frequently with <italic>GATA6</italic> LoF (14/27) than missense (9/43) variants (p=0.001).</p><p>Among 43 <italic>GATA6</italic> missense variants, 11 variants altered residues in the DNA-binding zinc finger (ZF) domain encoded by exon 4 (amino acids 435–477), significantly more than expected by chance (p=0.0004). Nine of these 11 patients with exon four missense variants had pancreatic agenesis or congenital diaphragmatic hernia, but none of 32 patients with missense variants located elsewhere (p=1.1e-6). Within exon 4, recurrent missense mutations altered the basic arginine residue 456. Computational modeling of this domain (PyMOL software) positioned residue 456 alongside a polar residue (asparagine 466) in close proximity to DNA (<xref ref-type="bibr" rid="bib4">Bates et al., 2008</xref>; <xref ref-type="fig" rid="fig1">Figure 1C</xref>). Substitution of a non-polar glycine at residue 456 (R456G) is predicted to disrupt these interactions, and potentially alter GATA6 binding to DNA.</p></sec><sec id="s2-2"><title>Generation of <italic>GATA6</italic> LoF and <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSCs using CRISPR/Cas9</title><p>We created <italic>GATA6</italic> LoF hiPSCs using two independent guide RNAs (gRNAs) targeting exon 2 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) that were transfected with Cas9 endonuclease into an early passage healthy hiPSC line PGP1 (<xref ref-type="bibr" rid="bib44">Lee et al., 2009</xref>). Targeted hiPSCs were subcloned and <italic>GATA6</italic> variants were confirmed by next-generation and Sanger sequencing of PCR-amplified fragments (METHODS). Four independent mutant hiPSC lines were obtained: two carry a heterozygous 1 bp insertion (<italic>GATA6<sup>+/-</sup></italic>, chr18:19,752,124–19,752,124, A:TA) and two have a homozygous 1 bp deletion (<italic>GATA6<sup>-/-</sup></italic>, chr18:19,752,123–19,752,124, TA:T). Using similar strategies, we transfected a gRNA targeting exon four with a single-stranded DNA oligonucleotide to serve as a template for homology-directed repair and generated two hiPSC lines with homozygous missense variant R456G (<italic>GATA6<sup>R456G/R456G</sup></italic>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). No lines with a heterozygous R456G variant were obtained. In parallel we produced <italic>GATA6<sup>+/-</sup></italic>, <italic>GATA6<sup>-/-</sup></italic>, and <italic>GATA6<sup>R456G/R456G</sup></italic> variants in a PGP1 hiPSC line that carried expressed green fluorescent protein (GFP) fused to endogenous cardiac troponin T alleles (TNNT2-GFP; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>).</p></sec><sec id="s2-3"><title>Differentiation of <italic>GATA6</italic> mutant hiPSCs into hiPSC-CMs</title><p>Wildtype (WT)<italic>, GATA6<sup>+/-</sup></italic>, <italic>GATA6<sup>-/-</sup></italic>, and <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSCs were processed for differentiation into cardiomyocytes (hiPSC-CMs) by modulation of the Wnt signaling pathway and subsequent metabolic selection via glucose deprivation (<xref ref-type="bibr" rid="bib69">Sharma et al., 2018b</xref>). This protocol yields hiPSC-CMs that express first and second heart field genes (<xref ref-type="bibr" rid="bib88">Zhang et al., 2019</xref>). As previous single-cell RNA- sequencing (RNA-Seq) of cardiomyocytes isolated from developing mouse hearts (<xref ref-type="bibr" rid="bib19">DeLaughter et al., 2016</xref>) identified peak <italic>Gata6</italic> expression in cardiac progenitors and early cardiomyocytes, we studied hiPSC-CMs at differentiation days 4 and 8, which approximate these in vivo developmental stages. GATA6 protein expression and nuclear localization were reduced in <italic>GATA6<sup>+/-</sup></italic> compared to isogenic WT lines and absent in <italic>GATA6<sup>-/-</sup></italic> lines (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D,E</xref>). <italic>GATA6<sup>+/-</sup></italic> hiPSCs, unlike WT hiPSCs, exhibited mono-allelic <italic>GATA6</italic> expression, suggesting nonsense-mediated decay of RNAs transcribed from targeted alleles.</p><p>We assessed sarcomere production as a measure of cardiomyocyte differentiation in the TNNT2-GFP lines. <italic>GATA6<sup>+/-</sup></italic> hiPSC-CMs had weaker fluorescent signal than WT cells, while <italic>GATA6<sup>-/-</sup></italic> lines expressed no fluorescence at baseline or during the differentiation protocol (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>). Consistent with these data, at differentiation day eight when contracting sarcomeres were present in WT cells, fewer independent differentiation rounds of <italic>GATA6<sup>+/-</sup></italic> hiPSC-CMs contained beating sarcomeres and no <italic>GATA6<sup>-/-</sup></italic> cells showed sarcomeres or spontaneous beating (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Analogous studies of <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSC-CMs (<xref ref-type="fig" rid="fig2">Figure 2D–F</xref>) showed a fluorescence signal comparable to that of <italic>GATA6<sup>+/-</sup></italic> hiPSC-CMs and spontaneous beating cells in approximately ~60% of differentiation rounds.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>GATA6</italic> mutant hiPSCs exhibit hiPSC-CM differentiation defects.</title><p>(<bold>A</bold>) <italic>GATA6</italic> variants in a TNNT2-GFP reporter line showed reduced (<italic>GATA6<sup>+/-</sup></italic>) or absent (<italic>GATA6<sup>-/-</sup></italic>) GFP-tagged sarcomeres in comparison to WT cells. (<bold>B</bold>) Distribution of dissociated GFP-TNNT2-<italic>GATA6</italic> mutant cells assessed using the Countess system with a GFP filter cube (METHODS). (<bold>C</bold>) Number of <italic>GATA6</italic> LoF mutant differentiation cultures (n = 25 per genotype) with beating hiPSC-CMs. (<bold>D</bold>) The <italic>GATA6<sup>R456G/R456G</sup></italic> variant has reduced expression of GFP-tagged sarcomeres. (<bold>E</bold>) Fluorescence distribution of differentiated GFP-TNNT2 <italic>GATA6<sup>R456G/R456G</sup></italic> cells assessed using the Countess system with a GFP filter cube (see Materials and methods). (<bold>F</bold>) Number of GFP-TNNT2 <italic>GATA6<sup>R456G/R456G</sup></italic> differentiation cultures (n = 25) with beating day eight hiPSC-CMs. All lines were studied at differentiation day 8. Significance was assessed using Student’s t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Sequence and phenotype characterization of <italic>GATA6</italic> mutant hiPSCs.</title><p>(<bold>A</bold>) Sanger and next-generation sequencing (depicted by Integrated Genomics Viewer; IGV) analysis of <italic>GATA6<sup>+/-</sup></italic> and <italic>GATA6<sup>-/-</sup></italic> lines. <italic>GATA6<sup>+/-</sup></italic> lines carry a 1 bp T insertion on one allele. <italic>GATA6<sup>-/-</sup></italic> lines carry a 1 bp A deletion on both alleles. (<bold>B</bold>) <italic>GATA6<sup>R456G/R456G</sup></italic> lines carry a silent C:A (PAM site mutation) and C:G missense, leading to the R456G missense mutation. (<bold>C</bold>) Pluripotency evaluation of hiPSC lines. Undifferentiated hiPSC cells were subjected to immunofluorescence for pluripotency markers OCT4 and TRA-1–81. Top row: CRISPR genome-edited cells generated in the PGP1 background. Bottom row: CRISPR genome-edited cells generated in the TNNT2-GFP background. (<bold>D</bold>) Immunofluorescence of day 4 confirms absence of GATA6 protein in <italic>GATA6</italic><sup>-/-</sup> cells. (<bold>E</bold>) Western blots of extracts from <italic>GATA6<sup>+/-</sup></italic> and <italic>GATA6<sup>-/-</sup></italic> lines probed with TNNT2 and GATA6 antibodies. Vinculin levels provide a loading control for each blot. N = 3 independent experiments conducted for each western blot. (<bold>F</bold>) Gene expression analysis in day 8 <italic>GATA6<sup>+/-</sup></italic> and <italic>GATA6<sup>-/-</sup></italic> lines reveals differential expression of cardiac-specific genes. Using the pheatmap and Venn Diagram R scripts, these illustrations were generated for day 8.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Transcriptional analysis of <italic>GATA6</italic> LoF hiPSC-CMs</title><p>We assessed transcriptional responses to altered <italic>GATA6</italic> levels throughout hiPSC-CM differentiation by bulk RNA-Seq analyses of cultures at days 0, 4, 8, 12, and 30 (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), and by single-cell RNA-Seq on days 4 and 8 (<xref ref-type="fig" rid="fig4">Figure 4</xref>) that precedes metabolic selection and enriches cultures for cardiomyocytes. All cells were differentiated, processed, and harvested in parallel. RNA-Seq data was aligned and processed to limit potential batch effects, and clustered using methods implemented in DESEQ2 (bulk) or Seurat (single cell) (METHODS). We observed consistency between bulk and single-cell expression data. In addition, principal component analyses (PCA) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>) of independent, genotype-identical lines demonstrated close clustering of RNA expression, indicating that <italic>GATA6</italic> genotype and differentiation stage largely accounted for differences in gene expression.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>GATA6</italic> mutant cells exhibit downregulation of second heart field-related genes during hiPSC-CM differentiation.</title><p><bold>A</bold>) Gene expression principal component analysis (PCA) of day 0–30 WT (<italic>GATA6<sup>+/+</sup></italic>), <italic>GATA6<sup>+/-</sup></italic>, <italic>GATA6<sup>-/-</sup></italic>, and <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSC-CMs. RNA-Seq samples were harvested in duplicate for all time points. (<bold>B</bold>) Venn Diagrams (left) and heat map (right) of day 4 <italic>GATA6<sup>+/-</sup></italic> and <italic>GATA6<sup>-/-</sup></italic> cells. In the heatmap, red indicates upregulated genes whereas blue represents downregulated genes. Samples are in duplicate. Selected second heart field genes are shown. (<bold>C</bold>) Expression data in normalized counts for second heart field-related genes (top row), cardiac developmental transcription factors (middle row), sarcomere, and other selected genes (bottom row) during differentiation of <italic>GATA6</italic> mutant hiPSC-CMs. Data represented as mean ± SD. Note that <italic>SMYD1</italic> and <italic>HAND2</italic> graphs are plotted with logarithmic scale. (<bold>D</bold>) Gene expression scatterplot illustrating downregulation of expression of <italic>HAND2</italic> upstream and downstream gene network in day 4 <italic>GATA6<sup>+/-</sup></italic> and <italic>GATA6<sup>-/-</sup></italic> cells. X-axis, log2 fold-change of gene expression in <italic>GATA6<sup>-/-</sup></italic> cells relative to WT. Y-axis, log2-fold-change of gene expression in <italic>GATA6<sup>+/-</sup></italic> cells relative to WT. Canonical cardiac development and the second heart field genes are bolded.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title><italic>GATA6</italic> mutant cells exhibit an upregulation in epithelial-to-mesenchymal transition, neurodevelopmental, and neural crest-related genes.</title><p>(<bold>A</bold>) Expression of epithelial-to-mesenchymal transition markers in <italic>GATA6</italic> mutant hiPSC-CMs during differentiation. (<bold>B</bold>) Expression of neurodevelopmental and neural crest-related genes in <italic>GATA6</italic> mutant hiPSC-CMs during differentiation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig3-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Single-cell transcriptional analysis of <italic>GATA6</italic> mutant hiPSC-CMs during differentiation.</title><p>(<bold>A</bold>) tSNE of single-cell RNA-Seq of day 4 <italic>GATA6</italic> mutant hiPSC-CMs identified four clusters. Labels reflect marker gene expression: SC, Stem cell; CPC, cardiac progenitor cells; E-CPC, cardiac progenitors enriched with endoderm markers; ECM, endodermal-like cells enriched for extracellular matrix proteins. (<bold>B</bold>) Examples of marker gene expression in clustered hiPSC-derived cells. CPC cells express mesodermal factors (<italic>MESP1, EOMES</italic>) as well as cardiac transcription factors (<italic>GATA6, GATA4, ISL1, NKX2.5</italic>, <italic>HAND1</italic>, and <italic>HAND2</italic>). SCs expressed OCT4 (<italic>POU5F1</italic>). E-CPCs expressed <italic>GATA6</italic>, <italic>SOX17</italic>, <italic>HNF4A</italic>, and <italic>FOXA2</italic>. (<bold>C</bold>) tSNE clustering of single-cell RNA-Seq of day 8 <italic>GATA6</italic> mutant hiPSC-CMs identified five clusters. Labels reflect marker gene expression: CM, cardiomyocytes; CM (‘RA’), cardiomyocytes with increased RA-signaling pathway genes; SC, Stem Cell; CM (‘Endo’), cardiomyocytes with enrichment in endothelial genes; FB; fibroblast-like cells (<bold>D</bold>) Examples of marker gene expression in clustered cells. SC expressed OCT4 (<italic>POU5F1</italic>). CMs expressed sarcomere protein genes (<italic>MYH6, MYH7</italic>), <italic>SMYD1</italic>, a CM-specific histone methyl-transferase, and <italic>HAND2,</italic> a second heart field transcription factor. CMs (RA) also expressed retinoic acid pathway genes (<italic>SOX6</italic>, <italic>HOXB1).</italic> CMs (Endo) have upregulated endothelial cell gene expression (<italic>MEF2C</italic>, <italic>BMPER</italic>), while FB cells expressed ECM markers (<italic>IGFBP7</italic>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>retinoic acid inhibitor (RA inh) treatment of <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSCs partially rescues cardiac progenitor gene expression.</title><p>(<bold>A</bold>) Gene Ontology analysis of genes differentially expressed (1.5-fold, p&lt;0.05) in WT hiPSCs treated with 1 µM RA inhibitor at day 4 of differentiation for 24 hr (WIN 18446, Tocris) vs. DMSO treatment. (<bold>B</bold>) Gene Ontology analysis of genes differentially expressed (1.5-fold, p&lt;0.05) in <italic>GATA6<sup>R456G/R456G</sup></italic>hiPSCs treated with 1 µM RA inhibitor at day 4 of differentiation for 24 hr (WIN 18446, Tocris) vs. DMSO treatment. (<bold>C</bold>) Normalized RNA-seq counts for retinoic acid signaling genes <italic>HOXA1</italic> and <italic>HOXB1</italic> showing rescue of retinoic acid signaling in <italic>GATA6<sup>R456G/R456G</sup></italic> day 5 cells. (<bold>D</bold>) Log2 fold-change for cardiac genes <italic>HAND2</italic> and <italic>KDR</italic> demonstrates these more drastically affected in <italic>GATA6<sup>R456G/R456G</sup></italic> cells (treated vs. untreated). (<bold>E</bold>) Heatmap of <italic>GATA6<sup>R456G/R456G</sup></italic> genes that are rescued upon RA inhibitor treatment (1.5-fold, p&lt;0.05). (<bold>F</bold>) Log2 fold-change of select genes from (<bold>E</bold>). Yellow bars represent the log2FC between DMSO-treated <italic>GATA6<sup>R456G/R456G</sup></italic> cells and DMSO-treated WT cells, while orange bars represent the log2FC between RA inhibitor-treated <italic>GATA6<sup>R456G/R456G</sup></italic> cells and DMSO-treated WT cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig4-figsupp1-v2.tif"/></fig></fig-group><p>At day 4 of differentiation, RNA-Seq of WT cells showed expression of both pluripotent stem cell markers (e.g., <italic>POU5F1</italic> encoding OCT4) and transcriptional modulators associated with early cardiomyocyte differentiation (<xref ref-type="fig" rid="fig3">Figures 3B,C</xref> and <xref ref-type="fig" rid="fig4">4A,B</xref>). These primordial cardiomyocytes expressed <italic>SMYD1</italic> (SET and MYND domain-containing protein-1), a nuclear histone methyl-transferase involved in remodeling chromatin and sarcomere assembly (<xref ref-type="bibr" rid="bib47">Li et al., 2011</xref>), Tbox transcription factors <italic>TBX5</italic> and <italic>TBX20,</italic> two of the earliest markers of cardiac development (<xref ref-type="bibr" rid="bib8">Bruneau et al., 2001</xref>; <xref ref-type="bibr" rid="bib77">Takeuchi et al., 2005</xref>), and <italic>MEF2C</italic>, an essential transcription factor for sarcomere assembly and function (<xref ref-type="bibr" rid="bib49">Lin et al., 1997</xref>). From day eight onward, the expression of stem cell marker genes was extinguished while expression of cardiomyocyte differentiation transcripts increased (<xref ref-type="fig" rid="fig3">Figures 3C</xref> and <xref ref-type="fig" rid="fig4">4C,D</xref>).</p><p>Our protocol for cardiomyocyte differentiation also yielded subpopulations of cells expressing endodermal genes. Day 4 WT cells expressed hepatocyte nuclear factor family members (<italic>HNF1</italic>, <italic>HNF4A</italic>, <italic>HNF4B</italic>) that are depleted in <italic>Gata6</italic>-null mice (<xref ref-type="bibr" rid="bib63">Morrisey et al., 1998</xref>), <italic>FOXA1</italic> and <italic>FOXA2</italic>, transcription factors that activate expression of the pancreas/duodenum homeobox-1 gene <italic>PDX1</italic>, which is essential for pancreas development and β islet cell differentiation (<xref ref-type="bibr" rid="bib24">Gao et al., 2008</xref>; <xref ref-type="bibr" rid="bib27">Gerrish et al., 2001</xref>; <xref ref-type="bibr" rid="bib45">Lee et al., 2019</xref>; <xref ref-type="bibr" rid="bib90">Zhou et al., 2008</xref>) and other endodermal markers such as <italic>SOX17</italic> (<xref ref-type="bibr" rid="bib81">Wang et al., 2011</xref>; <xref ref-type="fig" rid="fig4">Figure 4A,B</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). <italic>PDX1</italic> was expressed through differentiation day 12 in WT lines, but not after metabolic enrichment for cardiomyocytes.</p><p><italic>GATA6<sup>+/-</sup></italic> cells at day 4 of differentiation had lower transcript levels of primordial cardiomyocyte genes compared to WT cells (<xref ref-type="fig" rid="fig3">Figure 3B,C</xref>) and gene ontology (GO) analyses inferred that pathways involved in cardiac muscle contraction, development, and chamber organization were reduced. Notably, the expression of <italic>SMYD1</italic>, which regulates the expression of <italic>HAND2,</italic> a critical transcriptional regulator of the second heart field (<xref ref-type="bibr" rid="bib30">Gottlieb et al., 2002</xref>; <xref ref-type="bibr" rid="bib43">Laurent et al., 2017</xref>) that gives rise to the outflow tract, was strikingly diminished (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Similarly, expression of multiple <italic>HAND2</italic> network genes was also lower than in WT cells (<xref ref-type="fig" rid="fig3">Figure 3C,D</xref>), including <italic>GATA</italic> gene family members<italic>, ISL1, MEF2C,</italic> and prototypic cardiac transcription factors <italic>MEIS-1, NKX2-5, TBX5,</italic> and <italic>TBX20</italic>.</p><p>Prompted by the transcriptional signatures in <italic>GATA6<sup>+/-</sup></italic> cells, we compared the heart malformations in 54 PCGC patients with damaging variants in 11 <italic>HAND2</italic>-network and second heart field genes (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1C</xref>) with patients who have <italic>GATA6</italic> mutations. Forty of these 54 patients also had outflow tract malformations, including all (n = 5) CHD patients with damaging de novo variants in <italic>TBX20</italic>.</p><p><italic>GATA6<sup>+/-</sup></italic> cells also identified dysregulation of other gene programs involved in forming the outflow tract. The transient peak expression in WT cells of <italic>HOXA1</italic>, <italic>HOXB1,</italic> and <italic>MSX1</italic>, which regulate the induction and expression of critical molecules involved in specifying neural crest cell development (<xref ref-type="bibr" rid="bib57">Makki and Capecchi, 2011</xref>; <xref ref-type="bibr" rid="bib72">Simões-Costa and Bronner, 2015</xref>; <xref ref-type="bibr" rid="bib79">Tvrdik and Capecchi, 2006</xref>), remained low throughout differentiation of <italic>GATA6<sup>+/-</sup></italic> cells. Notably, <italic>HOXB1</italic> also participates in specifying endoderm destined for pancreatic and other abdominal cell lineages (<xref ref-type="bibr" rid="bib34">Huang et al., 2002</xref>). Expression was also diminished of key molecules that couple outflow tract myocardium with developing vascular beds, including <italic>KDR</italic> (encoding vascular endothelial growth factor (VEGF) receptor-2) and the VEGF co-receptor, <italic>NRPI</italic> (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Human mutations in <italic>HOXA1 </italic>(<xref ref-type="bibr" rid="bib78">Tischfield et al., 2005</xref>) and <italic>KDR (</italic><xref ref-type="bibr" rid="bib67">Reuter et al., 2019</xref>) alleles cause cardiac outflow tract malformations. Our data infers a critical role for <italic>GATA6</italic> in orchestrating <italic>SMYD1-HAND2, VEGF</italic>, and neural crest network interactions during outflow tract morphogenesis.</p><p>Day 8 <italic>GATA6<sup>+/-</sup></italic> cells expressed many cardiomyocyte transcripts at levels found in WT lines, but single-cell RNA-Seq analyses demonstrated some persistent differences including reduced expression of <italic>MYH7</italic>, a defining transcript of mature cardiomyocytes (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig4">Figure 4C,D</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). Genes encoding other sarcomere proteins were reduced through day 12 in <italic>GATA6<sup>+/-</sup></italic> cells and abnormalities remained after metabolic enrichment for cardiomyocytes (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Compared to WT, day 30 <italic>GATA6<sup>+/-</sup></italic> cardiomyocytes had 10-fold higher expression levels of <italic>ISL1</italic> and 4-fold higher levels of fetal myosin transcripts (<italic>MYH6</italic>), suggesting developmental immaturity of <italic>GATA6</italic> mutant cardiomyocytes.</p><p>Endodermal lineage genes were variably misexpressed in differentiating <italic>GATA6<sup>+/-</sup></italic> cells. In comparison to WT cells, transcript levels were lower for <italic>GATA4, HNF1,</italic> and <italic>HNF4A</italic> but normal for <italic>FOXA1</italic> and <italic>FOXA2</italic> (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). The day 12 peak expression of <italic>PDX1</italic> in WT cells was absent in <italic>GATA6<sup>+/-</sup></italic> cells.</p><p><italic>GATA6<sup>+/-</sup></italic> cells also misexpressed transcription factors genes involved in diaphragm development. In day 8 cells transcripts encoding <italic>NR2F2</italic> (encoding a retinoic acid (RA) responsive transcription factor) were 2 to 3-fold higher while expression of <italic>ZFPM2</italic> (encoding a family member of the Friend of GATA (FOG) transcription factors) was half of WT levels. As damaging variants in these genes cause congenital diaphragmatic hernia (<xref ref-type="bibr" rid="bib39">Kardon et al., 2017</xref>), these data imply that <italic>GATA6</italic> haploinsufficiency causes diaphragmatic dysgenesis by disrupting <italic>NR2F2</italic> and <italic>ZFPM2</italic> gene programs (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p><p><italic>GATA6<sup>-/-</sup></italic> hiPSC had profound deficits in cardiomyocyte differentiation (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Transcripts associated with early mesoderm specification including <italic>MESP1</italic> and transcription factors associated with primordial cardiomyocytes were more depressed than in <italic>GATA6<sup>+/-</sup></italic> cells. These findings support prior observations that shRNA knockdown of <italic>GATA6</italic> reduces hiPSC-CM differentiation capacity (<xref ref-type="bibr" rid="bib82">Yoon et al., 2018</xref>). Given the absence of emerging cardiomyocytes, metabolic selection to further enrich for this lineage was not performed.</p><p>The expression of endodermal genes in <italic>GATA6<sup>-/-</sup></italic> hiPSCs was also abnormal. Throughout differentiation <italic>GATA4</italic> transcripts were 10-fold reduced, <italic>FOXA1</italic> and <italic>FOXA2</italic> were transiently expressed only at day 4, and <italic>HNF4A</italic> and <italic>PDX1</italic> expression were extinguished (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Dysregulated expression of <italic>NR2F2</italic> (increased) and <italic>ZFPM2</italic> (decreased) was also observed.</p><p>Single-cell RNA-Seq (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>) identified two <italic>GATA6<sup>-/-</sup></italic> populations. One population maintained high expression of the stem cell (SC) marker <italic>POU5F1</italic> throughout differentiation day 8, while the other (FB) had increased expression of fibroblast markers (<italic>COL3A1, IGFBP7</italic>), epithelial to mesenchymal transition markers (<italic>SNAIL1/2, MMP2, VIM</italic>) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), and neural differentiation genes (<italic>SHH, ZEB1/2, NCAM2</italic>) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A,B</xref>). Together these data inferred that <italic>GATA6<sup>-/-</sup></italic> cells, lacking the normal signals involved in specifying cardiomyocyte and endoderm lineages, adopted alternative differentiation programs.</p></sec><sec id="s2-5"><title>Transcriptional analysis of <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSC-CMs</title><p>Parallel analyses of isogenic <italic>GATA6<sup>R456G/R456G</sup></italic> lines showed shared and distinct transcriptional profiles from <italic>GATA6<sup>+/-</sup></italic> or <italic>GATA6<sup>-/-</sup></italic> cells. At days 4–12, primordial cardiomyocyte transcripts (<italic>GATA4</italic>, <italic>HAND2</italic>, and <italic>SMYD1</italic>) in <italic>GATA6<sup>R456G/R456G</sup></italic> lines were expressed at levels midway between <italic>GATA6<sup>+/-</sup></italic> and <italic>GATA6<sup>-/-</sup></italic> cells, but markedly below levels in WT cells (<xref ref-type="fig" rid="fig3">Figures 3C</xref> and <xref ref-type="fig" rid="fig4">4</xref>, and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p><p>Distinctive transcription profiles in differentiating <italic>GATA6<sup>R456G/R456G</sup></italic> cells (days 4–12) suggested aberrant RA signaling (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). <italic>ALDH1A2</italic> transcripts (encoding the enzyme that converts RA from retinaldehyde) were 50-fold higher than WT cells and the expression of <italic>RARA</italic>, <italic>RARB</italic> (RA receptors A and B), and <italic>STRA6</italic> (receptor for retinol uptake) were increased 2 to 3-fold. Transcripts encoding targets of RA signaling were also increased. <italic>HOXB1,</italic> which contains two RA-responsive elements, including one 6.5 kb 3’ of coding sequences that is critical for foregut expression (<xref ref-type="bibr" rid="bib34">Huang et al., 2002</xref>), was 100-fold increased at differentiation day 4 – a marked contrast to the depressed levels observed in <italic>GATA6<sup>+/-</sup></italic> cells.</p><p>RA signaling modulates neural crest cell development (<xref ref-type="bibr" rid="bib59">Martínez-Morales et al., 2011</xref>) and at day 4 <italic>GATA6<sup>R456G/R456G</sup></italic> cells had increased <italic>PAX3</italic> and <italic>PAX7</italic> expression (100-fold and 3-fold, respectively; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). <italic>HOXA1</italic> (6-fold increased) and <italic>HOXB</italic> contribute to activating expression of <italic>ZIC1</italic> (8-fold increased) (<xref ref-type="bibr" rid="bib36">Jaurena et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Makki and Capecchi, 2011</xref>; <xref ref-type="bibr" rid="bib79">Tvrdik and Capecchi, 2006</xref>) that with <italic>PAX3/7</italic> induce and specify a neural crest gene program. <italic>PAX3</italic> also promotes neural crest migration into the cardiac outflow tract development (<xref ref-type="bibr" rid="bib16">Conway et al., 1997</xref>) and like <italic>STRA6,</italic> (<xref ref-type="bibr" rid="bib15">Coles and Ackerman, 2013</xref>) and contributes to diaphragm development (<xref ref-type="bibr" rid="bib75">Stuelsatz et al., 2012</xref>) by specifying paraxial mesoderm (<xref ref-type="bibr" rid="bib54">Magli et al., 2019</xref>). Aberrant RA signaling may contributed to dysregulation of other developmental regulators of diaphragm formation, including <italic>NR2F2</italic> (~8-fold increased) and <italic>ZFPM2</italic> (5- to 12-fold decreased).</p><p>We further assessed activation of RA signaling by comparing RNA-Seq analyses of day 4 differentiating WT and <italic>GATA6<sup>R456G/R456G</sup></italic> cells that were cultured with or without an inhibitor of the ALDH1A2 enzyme (METHODS). Treated WT cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) had significantly altered expression (p&lt;0.05, 1.5-fold), decreasing the expression of transcripts assigned to Gene Ontology terms for heart and muscle cell differentiation and increasing endodermal fate specification and Wnt signaling transcripts. Treated <italic>GATA6<sup>R456G/R456G</sup></italic> cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>) had increased expression of transcripts assigned to Gene Ontology terms for myoblast differentiation, circulatory system development and anatomical structures. Notably, the expression of 25% of genes in treated <italic>GATA6<sup>R456G/R456G</sup></italic> cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C–F</xref>) had levels found in untreated WT cells (<italic>HOXB1</italic> and <italic>FOXH1</italic>) or normalized levels, approaching those in untreated WT cells (<italic>HOXA1</italic>, <italic>HAND2</italic>, <italic>RARB, TBX20)</italic>.</p><p><italic>GATA6<sup>R456G/R456G</sup></italic> cells had aberrant expression of other endoderm genes, including markedly lower transcripts of <italic>HNF</italic> gene family members and striking loss (≥100-fold below WT) of <italic>FOXA1</italic> and <italic>FOXA2</italic> expression (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Biallelic deletion of <italic>FOXA2</italic> in human stem cells prevents pancreatic specification (<xref ref-type="bibr" rid="bib45">Lee et al., 2019</xref>). <italic>GATA6<sup>R456G/R456G</sup></italic> cells also had increased expression of <italic>SOX6</italic>, which represses <italic>PDX1</italic>-dependent transcriptional activation of the insulin gene, <italic>INS</italic> (<xref ref-type="bibr" rid="bib35">Iguchi et al., 2005</xref>). The cumulative effect of these deficits could account for the extinguished expression of <italic>PDX1</italic> and contribute to the high association of pancreatic agenesis with heterozygous <italic>GATA6<sup>R456G</sup></italic> mutations (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>Despite multiple transcriptional abnormalities, metabolic enrichment yielded <italic>GATA6<sup>R456G/R456G</sup></italic> cardiomyocytes (day 30) with prototypic gene expression. However, like <italic>GATA6<sup>+/-</sup></italic> hiPSC-CMs, <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSC-CMs exhibited a higher <italic>MYH6:MYH7</italic> transcript ratio than WT, indicating immaturity.</p></sec><sec id="s2-6"><title>GATA6 is a pioneer factor for cardiac development</title><p>We studied potential mechanisms by which <italic>GATA6</italic> regulated gene transcription by performing Assays for Transposase-Accessible Chromatin sequencing (ATAC-seq), GATA6 chromatin immunoprecipitation sequencing (ChIP-seq) and Hypergeometric Optimization of Motif EnRichment (HOMER) analyses at day 4 (<xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="fig" rid="fig6">Figure 6</xref>) and day 8 (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). ChIP-seq of <italic>GATA6<sup>-/-</sup></italic> cells yielded very few peaks above background (data not shown), confirming antibody specificity.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>GATA6 is a pioneer factor for cardiac development.</title><p>ATAC-seq and GATA6 ChIP-seq were performed in WT and mutant day 4 hiPSCs and overlapped to assess GATA6 direct binding to open vs. closed chromatin. (<bold>A</bold>) Approximately 12% of GATA6 ChIP-seq peaks overlapped with an ATAC-seq peak and were characterized as ‘Open’. The genomic location of these ChIP-seq peaks in open chromatin were characterized with respect to gene bodies, and DNA-binding motif enrichment was performed using HOMER analysis (METHODS). When GATA6 binds to open regions of chromatin, peaks are enriched for the GATA motif. (<bold>B</bold>) The remaining 88% of GATA6 ChIP-seq peaks were characterized as ‘Closed’. The genomic location of these ChIP-seq peaks were characterized with respect to gene bodies, and DNA-binding motif enrichment was performed using HOMER analysis. When GATA6 binds to closed regions of chromatin, peaks are enriched for the MEF2 motif. (<bold>C</bold>) Of the 20932 WT GATA6 ChIP-seq peaks, 39.3% were reduced in <italic>GATA6<sup>R456G/R456G</sup></italic> cells (adjusted p&lt;1e-4, two fold). These peaks were enriched for the GATA and HAND2 binding motifs by HOMER analysis. (<bold>D</bold>) Of the 67652 <italic>GATA6<sup>R456G/R456G</sup></italic> ChIP-seq peaks, 64.8% were upregulated in <italic>GATA6<sup>R456G/R456G</sup></italic> cells (adjusted p&lt;1e-4, two fold). These peaks were enriched for the REST and SOX binding motifs by HOMER analysis. (<bold>E</bold>) Peaks diminished in <italic>GATA6<sup>R456G/R456G</sup></italic> cells were overlapped with WT ATAC-seq data to establish chromatin accessibility. Almost 21% of peaks diminished in <italic>GATA6<sup>R456G/R456G</sup></italic> cells were in open chromatin regions; these peaks were enriched for the GATA and HAND motifs. (<bold>F</bold>) Peaks upregulated in <italic>GATA6<sup>R456G/R456G</sup></italic> cells were overlapped with <italic>GATA6<sup>R456G/R456G</sup></italic> ATAC-seq data to establish chromatin accessibility. Four percent of peaks enriched in <italic>GATA6<sup>R456G/R456G</sup></italic> cells were in open chromatin regions; these peaks were enriched for the CTCF and SP1 motifs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Differential gene expression analysis of GATA6-bound genes.</title><p>ChIP-seq peaks of interest were subset into regions that are ‘open’ (e.g. regions that overlapped with an ATAC-seq peak and are more likely to be associated with a GATA-binding motif) or ‘closed’ (e.g. regions that did not overlap with an ATAC-seq peak and are less likely to be associated with a GATA-binding motif). Next, each peak was associated with its nearest gene using the R package ChIP-Seeker, and differential expression of the gene sets was evaluated. Comparisons were performed using Fisher’s Exact test. (<bold>A</bold>) Overlap of GATA6 ChIP-seq peaks in WT day 4 hiPSCs with ATAC-seq data. Closed peaks were then analyzed for changes in gene expression (e.g. ‘pioneer peaks’). Of the 2878 genes that are activated between days 4 and 5, 583 genes are associated with a GATA6-bound closed peak. (<bold>B</bold>) GATA6 ChIP-seq peaks that were diminished (&gt;2 fold, p&lt;0.05) in <italic>GATA6<sup>+/-</sup></italic> day 4 hiPSCs were analyzed for open chromatin overlap and differential gene expression. The majority of differential peaks were associated with closed chromatin (89.3% vs. 88.1%, p=0.011), but differential gene expression was significantly more associated with open chromatin (8.0% vs. 5.6%, p=0.013). (<bold>C</bold>) GATA6 ChIP-seq peaks that were diminished (&gt;2 fold, p&lt;0.05) in <italic>GATA6<sup>R456G/R456G</sup></italic> day 4 hiPSCs were analyzed for open chromatin overlap and differential gene expression. Diminished peaks were significantly more likely to be associated with open chromatin (20.9% vs. 11.9%, p&lt;2.2e-16), and differential ChIP-seq peaks were more likely to be associated with differential gene expression in both open and closed peaks than <italic>GATA6<sup>+/-</sup></italic> differential ChIP-seq peaks (18.9% vs. 8.0%, p=3.4e-12 for open chromatin and 14.6% vs. 5.6%, p&lt;2.2e-16). (<bold>D</bold>) GATA6 ChIP-seq peaks that were upregulated (&gt;2 fold, p&lt;0.05) in <italic>GATA6<sup>R456G/R456G</sup></italic> day 4 hiPSCs were analyzed for open chromatin overlap and differential gene expression. Diminished peaks were significantly less likely to be associated with open chromatin (4.3% vs. 11.9%, p&lt;2.2e-16), and differential ChIP-seq peaks were more likely to be associated with differential gene expression in both open and closed peaks than <italic>GATA6<sup>+/-</sup></italic> differential ChIP-seq peaks (12.3% vs. 8.0%, p=1.9e-3 for open chromatin and 13.7% vs. 5.6%, p&lt;2.2e-16).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig5-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Epigenetic abnormalities in <italic>GATA6<sup>+/-</sup></italic> cells.</title><p>(<bold>A</bold>) Of the 20932 WT GATA6 ChIP-seq peaks, 39.3% were reduced in <italic>GATA6<sup>+/-</sup></italic> cells (adjusted p&lt;1e-4, two fold). These peaks were enriched for the GATA and EWS binding motifs by HOMER analysis. (<bold>B</bold>) Of the 17624 <italic>GATA6<sup>+/-</sup></italic> ChIP-seq peaks, 47% were upregulated in <italic>GATA6<sup>+/-</sup></italic> cells (adjusted p&lt;1e-4, two fold). These peaks were enriched for the USF2 and GATA-binding motifs by HOMER analysis. (<sc><bold>C</bold></sc>) Peaks diminished in <italic>GATA6<sup>+/-</sup></italic>cells were overlapped with WT ATAC-seq data to establish chromatin accessibility. Only 10.7% of peaks diminished in <italic>GATA6<sup>+/-</sup></italic> cells were in open chromatin regions; these peaks were enriched for the GATA and SP1 motifs. (<bold>F</bold>) Peaks upregulated in <italic>GATA6<sup>R456G/R456G</sup></italic> cells were overlapped with <italic>GATA6<sup>+/-</sup></italic> ATAC-seq data to establish chromatin accessibility. Only 2.4% of peaks enriched in <italic>GATA6<sup>+/-</sup></italic> cells were in open chromatin regions; these peaks were enriched for the SP1 and GATA motifs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>ATAC-seq analysis of cardiac genes in day 4 <italic>GATA6</italic> LoF and <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSC-CMs.</title><p>(<bold>A</bold>) Genomic location of all WT ATAC peaks at day 4. (<bold>B</bold>) Top DNA-binding motifs as identified by HOMER found in ATAC peaks in gene promoters. (<bold>C</bold>) Genomic location of all diminished ATAC peaks (at least 2-fold reduction in peak height) in <italic>GATA6</italic> mutants compared to WT. Solid lines indicate non-promoter peaks, dashed lines indicate promoter peaks. (<bold>D</bold>) Top DNA-binding motifs as identified by HOMER found in 2-fold diminished ATAC peaks in the promoters of downregulated genes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>ATAC-seq analysis of cardiac genes in day 8 <italic>GATA6</italic> LoF and <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSC-CMs.</title><p>(<bold>A</bold>) Genomic location of all WT ATAC peaks at day 4. (<bold>B</bold>) Top DNA-binding motifs as identified by HOMER found in ATAC peaks in gene promoters. (<bold>C</bold>) Genomic location of all diminished ATAC peaks (at least 2-fold reduction in peak height) in <italic>GATA6</italic> mutants compared to WT. Solid lines indicate non-promoter peaks, dashed lines indicate promoter peaks. (<bold>D</bold>) Top DNA-binding motifs as identified by HOMER found in 2-fold diminished ATAC peaks in the promoters of downregulated genes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig6-figsupp2-v2.tif"/></fig></fig-group><p>At day 4, <italic>GATA6</italic> bound ~21,000 open chromatin peaks genome-wide, of which ~ 21% are near promoters. Notably, only 12% of <italic>GATA6</italic>-bound open chromatin peaks overlapped with ATAC peaks and were markedly enriched for a GATA-binding motif (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). ChIP-seq data from day 8 cells were similar (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). These data inferred that GATA6 directly participates in regulating transcriptional activation of <italic>EOMES, GATA4, MEIS1/2, NKX2.5, TBX5</italic>, and <italic>TBX20</italic> (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>).</p><p>By contrast, 88% of GATA-bound peaks occurred in closed chromatin (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Sequences within these peaks were not enriched for the GATA motif but were highly enriched for the MEF2 binding motif. MEF2 proteins contain a DNA-binding domain (MADS) and transcriptional activating domain (TAD) (<xref ref-type="bibr" rid="bib2">Backs and Olson, 2006</xref>) that promote differentiation gene programs for cardiac, skeletal, and smooth muscle myocytes (<xref ref-type="bibr" rid="bib66">Potthoff and Olson, 2007</xref>). During cardiomyocyte differentiation of WT hiPSCs MEF2 transcripts increased 120-fold between days 4–8 (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). In comparison, at day 8–12, MEF2A and MEF2C levels were decreased in <italic>GATA6<sup>+/-</sup></italic> cells. As together, these data implied that GATA6 functioned as a cardiac pioneer factor, which has been proposed for other GATA proteins, we examined the correlation between GATA6 bound to closed chromatin at day 4 and gene expression at day 5 in WT cells. There were 2878 genes differentially expressed between day 4 and day 5 WT cells. Of those, 1049 were associated with GATA6-bound closed chromatin (36.4%). Among these, 583 (56%) genes had increased expression at day 5, including key cardiac developmental transcription factors, <italic>GATA4, SMYD1, KDR,</italic> and <italic>TBX5</italic> (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Based on these data, we propose that GATA6 is a cardiac development pioneer factor.</p></sec><sec id="s2-7"><title>Epigenetic abnormalities in <italic>GATA6</italic> mutant iPSCs</title><p>In comparison to WT, day 4 <italic>GATA6<sup>+/-</sup></italic> cells had~6500 diminished GATA6 ChIP-seq peaks and ~5800 diminished ATAC peaks (<xref ref-type="fig" rid="fig6">Figure 6A</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Diminished ATAC peaks in proximity to promoters were enriched for GATA, HAND, HNF, and SOX motifs (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, <xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), indicating that attenuated expression of these transcription factor family members could have direct functional consequences. Notably however, few diminished GATA-bound peaks resided within open chromatin (10.7%), of which only 35% were enriched for GATA motifs (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>, <xref ref-type="fig" rid="fig6">Figure 6C</xref>). Instead, and consistent with properties of a pioneer factor, <italic>GATA6<sup>+/-</sup></italic> cells had prominent loss (89%) and gain (97%) of GATA-bound peaks within closed chromatin (<xref ref-type="fig" rid="fig6">Figure 6B–D</xref>). From these data we infer that GATA interactions with closed chromatin are highly sensitive to protein dosage, while interactions with open chromatin at promoter regions remain relatively intact despite reduced GATA6 protein levels.</p><p>By contrast, day 4 <italic>GATA6<sup>-/-</sup></italic> cells contained~29,000 diminished ATAC-seq peaks of which ~ 31% resided in proximity to promoters (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Profiles at day 8 cells were similar (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). Notably, diminished ATAC peaks showed enrichment in the binding motif for <italic>NFY</italic> that encodes the ubiquitous promoter element binding factor of CCAAT-boxes. These data implied that extinguishing <italic>GATA6<sup>-/-</sup></italic> expression caused widespread deficits in promoter activation, which likely accounted for failed mesoderm specification and cardiomyocyte differentiation.</p><p>ChIP-seq analyses of <italic>GATA6<sup>R456G/R456G</sup></italic> cells (<xref ref-type="fig" rid="fig5">Figure 5C–F</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>) identified ~8000 diminished peaks. In comparison to other mutant lines, <italic>GATA6<sup>R456G/R456G</sup></italic> cells had a significantly higher proportion of diminished peaks (21%) in open chromatin that contained a GATA or HAND binding motif and 19% of these diminished peaks were associated with differential gene expression (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). Additionally, missense cells had a remarkable number (~44,000) of augmented and ectopic peaks. We suggest that these aberrant chromatin interactions reflected direct promiscuous GATA6<sup>R456G</sup> binding activity or perhaps occurred in response to aberrant RA signaling.</p><p>Among the upregulated peaks,~4% of these peaks had GATA-bound to open chromatin, with enrichment of the CTCF binding motif. Furthermore,~12% were associated with differential gene expression, including <italic>MSX1, FOXA1, MEIS2, HCN4,</italic> and <italic>HOXA2 </italic>(<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). However, the vast majority of increased or ectopic peaks (96%) resided within closed chromatin and lacked the GATA6 binding motif. Even so, 14% of the differential closed peaks were associated with differential gene expression, including peaks in <italic>TBX20, FOXA1</italic>, and <italic>FOXH1</italic>. Our data suggest that the GATA6<sup>R456G</sup> variant impairs binding to the GATA motif, reducing normal GATA6 function, and also promotes promiscuous binding with either repressive or activating transcriptional effects.</p></sec><sec id="s2-8"><title>Phenotypes associated with epigenetic abnormalities in <italic>GATA6</italic> mutant iPSCs</title><p>We examined ATAC-seq and GATA6-ChIP-seq data to identify potential mechanisms for altered gene transcription with relevance to clinical phenotypes in CHD patients with pathogenic GATA6 variants. GATA6-bound peaks were universally decreased in <italic>GATA6<sup>+/-</sup></italic> cells, including those associated many cardiac developmental transcription factors genes (e.g., <italic>HAND2, KDR</italic>, and <italic>TBX5</italic> <xref ref-type="fig" rid="fig7">Figure 7A–C</xref>) and these changes were associated with normal or modest reduction in transcript levels (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). While many of these GATA6-bound peaks were also diminished in <italic>GATA6<sup>R456G/R456G</sup></italic> cells, the missense cells also had many enhanced and augmented peaks which were associated greater differential (decreased or increased) gene expression. For example, only <italic>GATA6<sup>R456G/R456G</sup></italic> cells had diminished GATA6-bound peaks identified in WT cells associated with <italic>GATA4</italic> (<xref ref-type="fig" rid="fig7">Figure 7D</xref>) and <italic>MEF2A</italic> and also new GATA6-bound peaks in <italic>MEF2C</italic>, <italic>ZIC1</italic> and <italic>ZIC3</italic> (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). The distinct epigenetic profiles in <italic>GATA6<sup>R456G/R456G</sup></italic> may contribute to the greater dysregulation of cardiac gene expression and cardiomyocyte maturation in comparison to <italic>GATA6<sup>+/-</sup></italic>cells (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref> A-C). However regardless of whether epigenetic changes in <italic>GATA6<sup>R456G/R456G</sup></italic> cells decreased normal gene expression or erroneously activated the expression of other genes, the associated cardiac consequence of altered transcription was similar to that of <italic>GATA6<sup>+/-</sup></italic>cells – disruption of cardiac outflow tract development (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>ATAC-seq and GATA6 ChIP-seq analysis of <italic>GATA6</italic> variant hiPSC-CMs reveals aberrant binding to congenital heart disease genes.</title><p>ATAC peaks (upper), GATA6 ChIP peaks (lower) and DNA-binding motifs (upper, boxed) found in day 4 <italic>GATA6</italic> LoF and <italic>GATA6<sup>R456G/R456G</sup></italic> cells, visualized using the Integrative Genomics Viewer (IGV) (<bold>A</bold>) Lost GATA6 ChIP-seq peak in the <italic>HAND2</italic> locus, with differential chromatin accessibility (ATAC-seq). (<bold>B</bold>) Lost GATA6 ChIP-seq peak at the <italic>KDR</italic> promoter, leading to reduced chromatin accessibility. (<bold>C</bold>) Lost GATA6 ChIP-seq peak in <italic>TBX5</italic>. (<bold>D</bold>) <italic>GATA6<sup>R456G</sup></italic> does not bind the <italic>GATA4</italic> locus in regions of open chromatin. (<bold>E</bold>) <italic>GATA6<sup>R456G</sup></italic> ectopically binds the <italic>ZIC3</italic> promoter.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>ATAC-seq and GATA6 ChIP-seq analysis of <italic>GATA6</italic> variant hiPSC-CMs reveals misregulation of pancreatic genes.</title><p>(<bold>A</bold>) ATAC peaks (upper), GATA6 ChIP peaks (lower) found in <italic>PDX1</italic> in day 4 <italic>GATA6</italic> LoF and <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSC-CMs, visualized using the Integrative Genomics Viewer (IGV). (<bold>B</bold>) ATAC peaks (upper), GATA6 ChIP peaks (lower), and DNA-binding motifs (upper, boxed) found in <italic>FOXA2</italic> in day 4 <italic>GATA6</italic> LoF and <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSC-CMs, visualized using the Integrative Genomics Viewer (IGV). (<bold>C</bold>) Bulk RNA-seq expression of pancreatic genes in <italic>GATA6</italic> cells throughout the course of cardiac differentiation. Data represented as mean ± SD.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>ATAC-seq and ChIP-seq of <italic>GATA6</italic> variant hiPSC-CMs reveals altered expression and chromatin accessibility in retinoic acid signaling-related genes.</title><p>(<bold>A</bold>) Gene-level ATAC-seq and GATA6 ChIP-seq analysis of retinoic acid signaling-related and neural crest-related genes of interest at day 4 and day 8 of hiPSC-CM differentiation. Boxed regions harbor DNA-binding motifs of interest. (<bold>B</bold>) Expression of retinoic acid signaling-related and neural crest-related genes of interest via bulk RNA-Seq. Data represented as mean ± SD. (<bold>C</bold>) Gene-level ATAC-seq and GATA6 ChIP-seq analysis at diaphragm gene <italic>STRA6</italic> at day 4 of hiPSC-CM differentiation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig7-figsupp2-v2.tif"/></fig></fig-group><p>By contrast, altered GATA6 binding and chromatin accessibility with accompanying dysregulated transcripts likely contributed to the extra-cardiac phenotypes that disproportionately affect patients with heterozygous <italic>GATA6</italic> R456G and other exon four missense variants. Pancreatic development requires cooperative <italic>GATA4 -GATA6</italic> interactions and compound <italic>Gata4-null</italic> and <italic>Gata6</italic>-haploinsufficient mice have reduced <italic>Pdx1</italic> expression, pancreatic agenesis or profound hypoplasia (<xref ref-type="bibr" rid="bib11">Carrasco et al., 2012</xref>). In addition to reduced occupancy of GATA6-motifs in <italic>GATA4</italic> with striking attenuated expression (<xref ref-type="fig" rid="fig7">Figure 7D</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>), GATA6 R456G also aberrantly bound chromatin associated with <italic>FOXA2</italic>, <italic>DEANR1</italic> (<italic>LINC00261</italic>), and <italic>PDX1</italic> and diminished transcription of these genes (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). <italic>DEANR1</italic> encodes a long noncoding RNA that specifies endoderm and pancreatic lineages by regulating the expression of <italic>FOXA2</italic> (<xref ref-type="bibr" rid="bib37">Jiang et al., 2015</xref>) which in turn regulates <italic>PDX1</italic> expression (<xref ref-type="bibr" rid="bib24">Gao et al., 2008</xref>).</p><p>Aberrant RA signaling may have contributed to the abnormal epigenetic profiles in <italic>GATA6<sup>R456G/R456G</sup></italic> cells. In missense cells, prominent ATAC peaks were identified in association with binding motifs for GATA, SOX6, HOX, and RARa in the promoter and exon 1 of <italic>ALDH1A2</italic> and transcript levels were increased. <italic>SOX6</italic> also had augmented ATAC peaks with RARa and GATA motifs, and GATA6<sup>R456G</sup> bound an intron one motif (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A–B</xref>). <italic>GATA6<sup>R456G/R456G</sup></italic> cells also showed increased ATAC peak heights with RARa binding motifs in close proximity to the reported RA-responsive element in <italic>HOXB1</italic> that promotes foregut expression. We also observe <italic>GATA6<sup>R456G</sup></italic> protein aberrantly bound to the <italic>STRA6</italic> locus, potentially affecting expression of this gene (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2C</xref>) These data suggest multiple direct and indirect epigenetic mechanisms by which the <italic>GATA6<sup>R456G</sup></italic> variant distinctly perturbed gene programs and resulted in maldevelopment of the diaphragm, pancreas and other abdominal organs in addition to cause cardiovascular malformations.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>By combining the strengths of WES, CRISPR/Cas9 genome editing, and hiPSCs, we demonstrate molecular and developmental mechanisms by which damaging variants in <italic>GATA6</italic> cause cardiac and extra-cardiac congenital anomalies. Transcriptional and epigenetic analyses of differentiating cardiomyocytes from isogenic WT and mutant hiPSCs provide evidence that GATA6 functions as a pioneer factor that modifies chromatin accessibility and promotes the expression of gene networks involving HAND2, VEGFR and neural crest cells that enable second heart field development and patterning of the outflow tract and atria. Our data also supports critical roles for <italic>GATA6</italic> in endodermal and retinoic acid signaling gene networks that gives rise to the pancreas and diaphragm. We find that LoF <italic>GATA6</italic> variants repress epigenetic modification and transcriptional activity, while an exon 4 <italic>GATA6</italic> missense variant alters normal and also causes ectopic epigenetic effects that enhanced retinoic acid signaling resulting in profound deleterious consequences on gene expression. The selective transcriptional deficits evoked by these variants provides mechanistic insights into the high prevalence of particular heart malformation and associated pancreatic dysgenesis and congenital diaphragmatic hernias that occur in CHD patients with pathogenic <italic>GATA6</italic> variants (<xref ref-type="fig" rid="fig8">Figure 8</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Model for GATA6 transcriptional regulation of cardiac and pancreatic gene expression (see Discussion).</title><p>ChIP-seq and ATAC-seq data of WT hiPSCs identified GATA6 bound to closed chromatin in intergenic regions without a GATA-binding motif. Moreover, GATA6 binding was associated with temporal activation of transcription in nearby genes that activate cardiomyocyte and endoderm gene network. These findings indicate that <italic>GATA6</italic> engages chromatin and fosters a competent state for transcription factor binding and transcriptional activation, supporting the conclusion that GATA6 is a pioneer factor, as is suggested for other GATA proteins (<xref ref-type="bibr" rid="bib23">Fisher et al., 2017</xref>). Notably, nonsense-mediated decay of <italic>GATA6<sup>+/-</sup></italic> transcripts reduced GATA6 protein levels, altered chromatin accessibility and decreased gene transcription, implying that intergenic sites are sensitive to GATA6 dosage. In addition, GATA6 functions as a traditional transcription factor, binding GATA motifs in promoters and activating transcription. These functions were relatively insensitive to half normal GATA6 levels.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-fig8-v2.tif"/></fig><p>Our analyses demonstrate that some <italic>GATA6</italic> expression is required for lineage specification of human cardiomyocytes. When cultured to promote cardiomyocyte differentiation <italic>GATA6<sup>-/-</sup></italic> cells had markedly reduced promoter activation with <italic>NFY</italic> transcripts that encode the binding factor of CCAAT-box, a nearly ubiquitous promoter element. <italic>GATA6<sup>-/-</sup></italic> cells were viable but showed very limited transcriptional evidence of mesoderm specification and extinguished cardiomyocyte gene expression. Instead <italic>GATA6<sup>-/-</sup></italic> cells adopted a gene program suggestive of nonspecific cells with expression of neuroectodermal and fibroblast genes.</p><p>These observations are consistent with prior analyses of <italic>Gata6</italic> ablation in mice that exhibit early embryonic lethality due to defects in extraembryonic endoderm formation (<xref ref-type="bibr" rid="bib30">Gottlieb et al., 2002</xref>; <xref ref-type="bibr" rid="bib63">Morrisey et al., 1998</xref>; <xref ref-type="bibr" rid="bib89">Zhao et al., 2005</xref>). While a tetraploid complementation system reported circumvention of this defect (<xref ref-type="bibr" rid="bib89">Zhao et al., 2005</xref>), only diminutive <italic>Gata6</italic>-null embryos were recovered with poor tissue integrity and embryonic resorption after E10.5. Although reverse-transcription-PCR of ‘rescued’ E9.5 <italic>Gata6</italic>-null embryos identified transcripts associated with early cardiomyocyte lineages, similar transcripts were absent in <italic>GATA6<sup>-/-</sup></italic> hiPSCs from which no cardiomyocytes emerged. Perhaps these differences reflect diffusible factors from other cell lineages not present in hiPSCs cultured in vitro, species-specific dosage requirements, or other mechanisms.</p><p><italic>GATA6</italic> haploinsufficiency influenced cardiomyocyte differentiation. ATAC and GATA6 ChIP-seq peaks were depleted in multiple developmental cardiac genes including <italic>SMYD1</italic>, <italic>NKX2-5</italic>, and <italic>ISL1</italic> in <italic>GATA6<sup>+/-</sup></italic> lines. As <italic>SMYD1</italic> regulates <italic>HAND2</italic> expression (<xref ref-type="bibr" rid="bib30">Gottlieb et al., 2002</xref>), depression of <italic>SMYD1</italic> transcripts likely resulted in a cascade effect, depleting <italic>HAND2</italic>-network genes. Notably, transcriptional deficits did not persist at differentiation day 30 <italic>GATA6<sup>+/-</sup></italic> hiPSC-CMs when many cardiac transcription factors (<italic>SMYD1, HAND2</italic>, <italic>NKX2-5</italic>, <italic>GATA4</italic>, and <italic>MEIS1)</italic> were expressed at levels found in WT cells. We presume that a compensatory transcriptional mechanism restored sufficient expression of many gene programs. However, <italic>ISL1</italic> transcripts remained abnormally high, and expression profiles of fetal and adult myosins (high <italic>MYH6</italic> and low <italic>MYH7</italic>, respectively) indicated immaturity of <italic>GATA6<sup>+/-</sup></italic> hiPSC-CMs. Persistence of this developmental deficit in vivo could contribute to longitudinal adverse cardiac outcomes in patients with pathogenic <italic>GATA6</italic> variants.</p><p>Our cardiomyocyte differentiation protocol also activated endodermal gene programs and uncovered misexpression in mutant lines. Aberrant but variable epigenetic profiles were identified in <italic>GATA6<sup>+/-</sup></italic> cells and in <italic>GATA6<sup>R456G/R456G</sup></italic> cells that led to misexpression of <italic>HNF</italic> and <italic>FOXA</italic> gene family-members occurred in both mutant lines. For example, both mutant lines had diminished GATA6 binding of open chromatin binding to <italic>HNF1</italic> with reduced transcript levels. By contrast, only <italic>GATA6<sup>R456G/R456G</sup></italic> cells lacked GATA6 binding to open chromatin near <italic>DEANR1</italic> a regulator of <italic>FOXA2</italic> expression (<xref ref-type="bibr" rid="bib24">Gao et al., 2008</xref>). <italic>GATA6<sup>R456G/R456G</sup></italic> cell also reduced expression of <italic>GATA4.</italic> While these data illustrate multiple mechanisms for depleting <italic>PDX1</italic> expression and account for the prominent association of CHD and pancreatic agenesis in patients with <italic>GATA6</italic> LoF and exon four missense variants, the pathways leading to this shared consequence were strikingly different. Epigenetic changes observed in <italic>GATA6<sup>+/-</sup></italic> cells depleted normal GATA6 binding to chromatin with attenuated gene transcription. Epigenetic changes observed in <italic>GATA6<sup>R456G/R456G</sup></italic> cells were far more sweeping, repressing many more genes and erroneously activating others.</p><p>We found that <italic>GATA6<sup>R456G/R456G</sup></italic> cells strikingly increased activation of RA signaling. Indeed, early inhibition of excessive RA signaling normalized some of the many aberrant in <italic>GATA6<sup>R456G/R456G</sup></italic> cells. Transcriptional data showed increased expression of the RA biosynthetic enzyme encoded by <italic>ALDH1A2</italic> and of <italic>STRA6</italic>, which encodes the integral membrane receptor that triggers release and uptake of retinol from circulating retinol-binding protein (<xref ref-type="bibr" rid="bib14">Chen et al., 2016</xref>). As RARa motifs occur in ATAC peaks associated with <italic>HOXA2</italic>, <italic>HOXB1,</italic> and <italic>SOX6</italic> genes and others, we deduced that <italic>GATA6<sup>R456G/R456G</sup></italic> likely activates transcription of these genes by increasing RA signaling. Moreover, as ATAC peaks in the <italic>ALDH2A2</italic> contain SOX6-binding motifs, enhanced <italic>SOX6</italic> expression would increase RA biosynthesis that in turn would further increase <italic>STRA6</italic> expression (<xref ref-type="bibr" rid="bib6">Bouillet et al., 1997</xref>) to further amplify RA signaling.</p><p>Human congenital anomalies arise from inadequate and excessive expression of key developmental signaling genes. Our analyses support the conclusion that CHD, pancreatic malformations and congenital diaphragmatic hernia that occur in <italic>GATA6</italic> exon four missense mutants reflect both loss of physiologic levels of GATA6 and excessively activated RA signaling. Development of the second heart field and neural crest cell migration into the nascent outflow tract is regulated by RA signaling (<xref ref-type="bibr" rid="bib85">Zaffran and Kelly, 2012</xref>), and when inappropriate, cardiac morphogenesis is perturbed (<xref ref-type="bibr" rid="bib65">Perl and Waxman, 2019</xref>). RA signaling also regulates transcriptional signals to develop the diaphragm (<xref ref-type="bibr" rid="bib39">Kardon et al., 2017</xref>), particularly formation of the central tendon (<xref ref-type="bibr" rid="bib15">Coles and Ackerman, 2013</xref>) around which diaphragmatic myocytes are patterned. As RA signals inhibit the expression of myogenic specification genes, including <italic>PAX3</italic> (<xref ref-type="bibr" rid="bib21">El Haddad et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Magli et al., 2019</xref>), excessive RA signaling could impair diaphragm formation by impairing tendon development in addition to altering differentiation and maturation of diaphragmatic myocytes. Increased RA signaling also augments <italic>SOX6</italic> expression, which attenuates <italic>PDX1</italic> activation of insulin signaling. When combined with deficient expression in critical endodermal genes (<italic>FOXa1 FOXa2</italic>), specification and differentiation of pancreatic progenitors are likely to be impaired. Consistent with these RA-mediated mechanisms, we note that human mutations in <italic>STRA6</italic> cause syndromic congenital diaphragmatic hernia with both CHD and pancreatic anomalies (<xref ref-type="bibr" rid="bib29">Golzio et al., 2007</xref>; <xref ref-type="bibr" rid="bib64">Pasutto et al., 2007</xref>).</p><p>Based on the heightened risk for congenital diaphragmatic hernia and pancreatic agenesis only among patients with missense variants within exon 4, we suggest that the encoded ZF domain in GATA6 has critical interactions with chromatin and DNA sequences that evoke the epigenetic and transcriptional consequences. Exon four missense residues perturb these functions- culminating in augmented RA signaling and extinguished <italic>PDX1</italic> expression. We suggest that missense variants residing outside of exon four do participate in these molecular processes, nor convey similar risks for developmental anomalies. Conformation of this hypothesis would improve clinical interpretation of <italic>GATA6</italic> genotypes.</p><p>Our studies also demonstrate that in vitro differentiation of hiPSCs evoke developmental gene expression profiles, independent of the many three-dimensional morphological cues that occur in vivo. This system has the potential to illuminate the consequences of lethal mutations that difficult to study in model organisms. While we recognize the limitations of cell models, by interpreting our molecular data with prior mouse studies and clinical studies of human patients, we believe that these iPSC studies provide valid molecular mechanism by which human <italic>GATA6</italic> mutations cause cardiac outflow tract defects, pancreatic agenesis, and congenital diaphragmatic hernias.</p><p>In conclusion, we show that genetic perturbation of a pioneer factor, GATA6, altered network-level transcriptional pathways that are critically involved in development of the heart (<italic>GATA4</italic>, <italic>HAND2</italic>), endodermal lineages (<italic>HNF</italic>, <italic>FOXA1, FOXA2</italic>), and pancreas (<italic>PDX1, SOX6</italic>) and diaphragm (<italic>NR2F2, STRA6, ZFPM2</italic>). Development of these organs is highly sensitive to changes in <italic>GATA6</italic> gene dosage from LoF variants and from missense variants in the second zinc-finger domain that alter RA signaling.</p><p>The combination of WES, genome sequencing data, CRISPR/Cas9 genome editing, and molecular analyses of developmentally immature human iPSC-derived lineages represents a valuable paradigm for mechanistic studies of human development. We expect that this platform will continue to illuminate molecular understandings of organogenesis that may improve clinical use of genetic data for personalized medicine.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Cell line (human)</td><td>PGP1</td><td><xref ref-type="bibr" rid="bib44">Lee et al., 2009</xref></td><td>GM23338</td><td>Male; mycoplasma-free</td></tr><tr><td>Cell line (human)</td><td>TNNT2-GFP</td><td>This paper</td><td/><td>Derived from PGP1 cell line GM23338, mycoplasma-free</td></tr><tr><td>Commercial assay or kit</td><td valign="top">Zero Blunt TOPO PCR Cloning Kit</td><td valign="top">ThermoFisher</td><td valign="top">K280002</td><td valign="top"/></tr><tr><td>Commercial assay or kit</td><td valign="top">Human Stem Cell Nucleofector Kit</td><td valign="top">Lonza</td><td valign="top">VPH-5022</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Nextera XT Sample Preparation Kit</td><td valign="top">Illumina</td><td valign="top">FC-131–1096</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Nextera DNA Sample Kit (ATAC-seq)</td><td valign="top">Illumina</td><td valign="top">FC-121–1030</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Tru ChIP Chromatin Shearing Hit</td><td valign="top">Covaris</td><td valign="top">520154</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Chromium i7 Multiplex Kit</td><td valign="top">10X Genomics</td><td valign="top">1000073</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Chromium Chip B Single-Cell Kit</td><td valign="top">10X Genomics</td><td valign="top">1000075</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Guide RNAs</td><td valign="top">This paper</td><td valign="top"/><td valign="top"><italic>GATA6</italic> Exon 2 Guide 1: GAGCCCCTACTCGCCCTACG <break/><italic>GATA6</italic> Exon 2 Guide 2: <break/>GCCCCTACTCGCCCTACGTG <break/><italic>GATA6</italic> Exon 4 Guide 1: <break/>GGCGTTTCTGCGCCATAAGG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">GATA6 sequencing primers</td><td valign="top">This paper</td><td valign="top">PCR Primers</td><td valign="top">GATA6 Exon 2 Sequencing Primer Left/Forward <break/>GACGTACCACCACCACCA <break/>GATA6 Exon 2 Sequencing Primer Right/Reverse <break/>CTTACCTGCACTGGGACCC <break/>GATA6 Exon 4 Sequencing Primer Left/Forward <break/>TGAATTCACGGAGACAGGCT <break/>GATA6 Exon 4 Sequencing Primer Right/Reverse <break/>TACAAGTGAGCAGAATACATGGCA</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">ATAC-seq amplification oligos</td><td valign="top"><xref ref-type="bibr" rid="bib10">Buenrostro et al., 2015</xref></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">Cas9 plasmid</td><td valign="top">Addgene</td><td valign="top">PX459v2</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">WIN 18446</td><td valign="top">Tocris</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">rabbit mono-clonal Gata6</td><td valign="top">Cell Signaling Technology</td><td valign="top">5851S</td><td valign="top">10 ug/ChIP</td></tr><tr><td valign="top">Antibody</td><td valign="top">rabbit mono-clonal Gata6</td><td valign="top">Abcam</td><td valign="top">Ab175927</td><td valign="top">1:1000 dilution</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">RNA-seq pipeline: bcbio-nextgen</td><td valign="top"><xref ref-type="bibr" rid="bib13">Chapman et al., 2020</xref></td><td valign="top">v.1.2.3</td><td valign="top">Hg19</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">R Package: DESEQ2</td><td valign="top"><xref ref-type="bibr" rid="bib52">Love et al., 2014</xref></td><td valign="top">v. 2.1.18.1</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">R Package: Seurat</td><td valign="top"><xref ref-type="bibr" rid="bib74">Stuart et al., 2019</xref></td><td valign="top">v.3.0.0</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">R Package: ChIP-seeker</td><td valign="top"><xref ref-type="bibr" rid="bib84">Yu et al., 2015</xref></td><td valign="top">v.1.14.1</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">HOMER</td><td valign="top"><xref ref-type="bibr" rid="bib31">Heinz et al., 2010</xref></td><td valign="top">v4.10.3</td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Human subjects</title><p>CHD subjects were recruited to the Congenital Heart Disease Network Study of the Pediatric Cardiac Genomics Consortium (CHD GENES: <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier NCT01196182) after approval from Institutional Review Boards as previously described (<xref ref-type="bibr" rid="bib38">Jin et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Gelb et al., 2013</xref>). Written informed consent was received from subjects or their parents prior to inclusion in the study. Any subject with CHD, regardless of age, race, or ethnicity was eligible for enrollment. Subjects with variants in GATA6 and 2<sup>nd</sup> heart field genes including CHD diagnoses, and extra-cardiac phenotypes are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-2"><title>Exome sequencing and analyses</title><p>DNA was extracted peripheral blood samples and captured using the Nimblegen v.2 exome capture reagent (Roche) or Nimblegen SeqxCap EZ MedExome Target Enrichment Kit (Roche) followed by Illumina DNA sequencing as previously described (<xref ref-type="bibr" rid="bib38">Jin et al., 2017</xref>). Reads were mapped to the reference genome (hg19), and further processed using the GATK Best Practices workflows as previously described (<xref ref-type="bibr" rid="bib38">Jin et al., 2017</xref>; <xref ref-type="bibr" rid="bib60">McKenna et al., 2010</xref>). Single nucleotide variants (SNVs) and small indels were called with GATK HaplotypeCaller and filtered for rarity (ExAC allele frequency ≤10–5) and quality as previously described (<xref ref-type="bibr" rid="bib38">Jin et al., 2017</xref>). The MetaSVM algorithm was used to predict deleteriousness of de novo missense mutations (annotated as ‘D-Mis’) using software defaults (<xref ref-type="bibr" rid="bib20">Dong et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Sulahian et al., 2014</xref>).</p></sec><sec id="s4-3"><title>TNNT2-GFP, <italic>GATA6<sup>+/-</sup></italic>, <italic>GATA6<sup>-/-</sup></italic>, and <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSCs and iPSC-CMs</title><p>All hiPSCs and hiPSC-CMs used here are derived from the male parent iPSC line PGP1 (<xref ref-type="bibr" rid="bib1">Akerman et al., 2017</xref>; RRID-GM23338) and are mycoplasma-free. The TNNT2-GFP iPSC line was generated by homology-directed repair, using a plasmid with the endogenous TNNT2 sequence connected to a GSSSS linker region, attached to the GFP gene, and the entire construct was flanked by 500 bp homology arms. PGP1 iPSCs were transfected as described (<xref ref-type="bibr" rid="bib69">Sharma et al., 2018b</xref>) to obtain homozygous integration of the GFP tag in both TNNT2 alleles. Edited clones were selected using puromycin and expanded and genotyped as previously described (<xref ref-type="bibr" rid="bib69">Sharma et al., 2018b</xref>) and differentiated into cardiomyocytes as described (<xref ref-type="bibr" rid="bib68">Sharma et al., 2018a</xref>).</p><p><italic>GATA6<sup>+/-</sup></italic> and <italic>GATA6<sup>-/-</sup></italic> hiPSCs were generated from TNNT2-GFP and PGP1 iPSCs by non-homologous end joining using a 2 µg plasmid expressing Cas9 (PX459v2 from Addgene) that was co-transfected with 2 µg plasmid expressing guide RNA (provided in Key Resource Table) using a stem cell nucleofector kit (Amaxa). Edited clones were selected using puromycin and expanded and genotyped as previously described (<xref ref-type="bibr" rid="bib69">Sharma et al., 2018b</xref>) and differentiated into cardiomyocytes as described (<xref ref-type="bibr" rid="bib68">Sharma et al., 2018a</xref>).</p><p><italic>GATA6<sup>R456G/R456G</sup></italic> hiPSCs were generated by homology-directed repair using a 2 µg plasmid expressing Cas9 (PX459v2 from Addgene) that was co-transfected with 2 µg plasmid expressing guide RNA (provided in Key Resource Table) and 2 µg single-stranded oligonucleotide (HDR template) using a stem cell nucleofector kit (Amaxa). Edited clones were selected using puromycin and expanded and genotyped as previously described (<xref ref-type="bibr" rid="bib69">Sharma et al., 2018b</xref>) and differentiated into cardiomyocytes as described (<xref ref-type="bibr" rid="bib68">Sharma et al., 2018a</xref>).</p></sec><sec id="s4-4"><title>Confirmation of editing in subcloned iPSC lines</title><p>All edited lines sub-cloned, by dissociating 1000 genome-edited hiPSCs cells, filtering through a 60 µm strainer, and evenly distributing them onto a 15 cm dish containing Matrigel and mTeSR+ rho kinase inhibitor. Individual monoclonal hiPSC colonies were picked when colony size reached approximately 200 cells and placed into individual separate wells of a 96 well plate. Clones were allowed to grow to 80% confluency, at which time a sample was obtained for PCR amplification to verify the <italic>GATA6</italic> variant or GFP-tagged <italic>TNNT2</italic> and to assess zygosity. PCR-amplified fragments (primers provided in Key Resource Table) containing putative variants were submitted for Sanger sequencing and next-generation sequencing. Sanger sequencing traces were deconvoluted using TIDE software to confirm zygosity. Clones carrying <italic>GATA6</italic> mutations were further expanded for subsequent culture and differentiation.</p></sec><sec id="s4-5"><title>hiPSC-CM differentiation</title><p>The hiPSC-CMs were generated from <italic>GATA6</italic> mutant hiPSCs using a small-molecule mediated differentiation approach that modulates Wnt signaling (<xref ref-type="bibr" rid="bib68">Sharma et al., 2018a</xref>). Cells began beating at approximately day 7 post-differentiation. Cardiomyocytes were metabolically selected from other differentiated cells by using glucose deprivation as previously described (<xref ref-type="bibr" rid="bib68">Sharma et al., 2018a</xref>). hiPSC-CM Western blots: GATA6 protein expression and nuclear localization were performed using <ext-link ext-link-type="uri" xlink:href="https://www.abcam.com/gata6-antibody-epr3990n-ab175927.html">ab175927</ext-link>.</p></sec><sec id="s4-6"><title>RNA-sequencing and analysis</title><p>RNA-seq experiments were performed on at least two independent cultured cell samples per time point, with the exception of <italic>GATA6<sup>R256G/R256G</sup></italic> DMSO control in the RA-signaling experiment. Trizol (Thermo Fisher) was used to harvest differentiating <italic>GATA6</italic> mutant hiPSC-CMs (days 0, 4, 8, 12, 30 of differentiation) designated for RNA-sequencing analysis. Samples harvested in Trizol were stored at −80°C until RNA was extracted. All RNA samples had an RNA integrity number of ≥8. Library preparation was conducted using the Nextera library preparation method. RNA-Seq library samples were pooled and run on four lanes (one flow cell) using the Illumina NextSeq500 platform. All data was combined into a single fastq file. Samples typically had 30–50M reads each. The raw reads were aligned by HISAT2 (v.2.1.0) to human genome (hg38). The aligned reads were quantified by FeatureCounts, counts were normalized, and differentially expressed genes were identified using DESeq2 (v1.24.0). DESeq2 data was analyzed and visualized in R using the ggplot2 (v3.1.0), pheatmap (v1.0.12), gProfiler (v0.6.7), and VennDiagram (v1.6.20) packages. Single-cell RNA-seq analysis for hiPSC-CMs was conducted using a 10x Genomics Chromium platform and analyzed in R using the Seurat (v. 3.5.1) pipeline. Seurat was used to regress out cell-cell variation in cell complexity, gene expression driven by batch, cell alignment rate, the number of detected molecules, and mitochondrial gene expression. Starting with Seurat v2.0, Seurat implements this regression as part of the data scaling process.</p></sec><sec id="s4-7"><title>ATAC-seq and Hi-C chromatin analysis</title><p>ATAC-seq was performed as previously described (<xref ref-type="bibr" rid="bib10">Buenrostro et al., 2015</xref>; <xref ref-type="bibr" rid="bib17">Corces et al., 2017</xref>). Briefly, 50,000 cells were harvested and lysed to isolate nuclei. Nuclei were treated with Tn5 transposase (Nextera DNA Sample Prep Kit, Illumina) and DNA was isolated. Fragmented DNA was amplified using bar-coded PCR primers (defined in <xref ref-type="bibr" rid="bib10">Buenrostro et al., 2015</xref>) and libraries were pooled. Pooled libraries were sequenced (Illumina Next-Seq) to a depth of 100 million reads per sample. Reads were aligned to the hg19 reference genome using BWA-MEM and peaks were called using HOMER (v4.10.3) (<ext-link ext-link-type="uri" xlink:href="http://homer.ucsd.edu/homer/index.html">http://homer.ucsd.edu/homer/index.html</ext-link>). Functional analysis of ATAC-seq peaks was performed using ChIP-Seeker (v.1.14.1). Motif enrichment was performed using HOMER (v4.10.3). Differential peaks were called using HOMER (v4.10.3).</p></sec><sec id="s4-8"><title>ChIP-seq</title><p>Cells (6-well plates) were grown to approximately 80% confluency and then fixed with 1% fresh formaldehyde diluted in media. Cells were quenched with glycine, washed, and harvested. Cell pellets were stored at −80°C. Cells were thawed and nuclei were prepared using the Covaris Tru ChIP Chromatin Shearing Kit (Covaris, MA, USA). Chromatin was sheared using the Covaris E210 to an average fragment size of 200–700 bp and an input sample was purified. Chromatin (5 µg) was incubated with GATA6 antibody (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_5851S">AB_5851S</ext-link>) at 4°C O/N and then added to Protein G beads for 2 hr at 4°C. Beads were washed and bound chromatin was eluted at 65°C for 30 min on a heated vortex. DNA was then purified and quantified. ChIP-seq libraries were prepared using Nextera XT DNA sample prep (Illumina). Sequences were aligned to hg19 using BWA-MEM. Peaks were called using MACS2 using default parameters with a q value of 0.001. Differential peaks were called using HOMERv4.10.3.</p></sec><sec id="s4-9"><title>Retinoic acid inhibitor treatment assay</title><p>hiPSCs were seeded and differentiated to day 4, and then treated for 24 hr with either DMSO or 1 µM WIN 18446 (Tocris), an inhibitor of the ALDH1A2 enzyme. Cells were harvested and processed for RNA-seq.</p></sec><sec id="s4-10"><title>Statistical analyses</title><p>The distribution of damaging human variants across the <italic>GATA6</italic> gene was analyzed using the binominal test, implemented in R. The association of <italic>GATA6<sup>+/-</sup></italic> and <italic>GATA6<sup>R456G/+</sup></italic> variants and pancreatic agenesis or congenital diaphragmatic hernia was analyzed using the Fisher Exact test, implemented in R. Transcriptional responses of iPSC-CMs with or without a <italic>GATA6</italic> variant was compared using the Student’s t-test was used for comparison. All error bars refer to standard deviation, unless otherwise specified. A p value of &lt; 0.05 was considered significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We gratefully acknowledge the NHLBI Pediatric Cardiac Genomics Consortium (PCGC) and Cardiovascular Development Consortium (CVDC) investigators for their support and expertise regarding the mechanisms driving congenital heart disease. Funding support for this study was provided in part by the NHLBI CVDC (U01HL098166) PCGC grants (U01-HL098188, U01-HL098147, U01-HL098153, U01-HL098163, U01-HL098123 and U01-HL098162), Fondation Leducq, the Engineering Research Centers Program of the National Science Foundation (NSF Cooperative Agreement No. EEC-1647837), NIH T32 HL116273, the Wellcome Trust (Sir Henry Wellcome fellowship), the German Academic Scholarship Foundation, and the Howard Hughes Medical Institute.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con7"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con8"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Investigation</p></fn><fn fn-type="con" id="con13"><p>Investigation</p></fn><fn fn-type="con" id="con14"><p>Investigation</p></fn><fn fn-type="con" id="con15"><p>Investigation</p></fn><fn fn-type="con" id="con16"><p>Investigation</p></fn><fn fn-type="con" id="con17"><p>Investigation</p></fn><fn fn-type="con" id="con18"><p>Investigation</p></fn><fn fn-type="con" id="con19"><p>Investigation</p></fn><fn fn-type="con" id="con20"><p>Investigation</p></fn><fn fn-type="con" id="con21"><p>Investigation</p></fn><fn fn-type="con" id="con22"><p>Investigation</p></fn><fn fn-type="con" id="con23"><p>Investigation</p></fn><fn fn-type="con" id="con24"><p>Investigation</p></fn><fn fn-type="con" id="con25"><p>Investigation</p></fn><fn fn-type="con" id="con26"><p>Conceptualization, Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con27"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con28"><p>Resources</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: CHD subjects were recruited to the Congenital Heart Disease Network Study of the Pediatric Cardiac Genomics Consortium (CHD GENES: ClinicalTrials.gov identifier NCT01196182) after approval from Institutional Review Boards as previously described (Pediatric Cardiac Genomics et al., 2013; Jin et al., 2017). Written informed consent was received from subjects or their parents prior to inclusion in the study. Clinical diagnoses were standardized based on review of medical data and family interviews.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Damaging Variants in <italic>GATA6</italic> and Second Heart Field Genes Associated with CHD and Extra-Cardiac Phenotypes.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53278-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Differential Genes Expressed in <italic>GATA6</italic> Mutant iPSCs and iPSC-CMs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53278-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>RNA-Seq-based principal component analysis (PCA) for GATA6 LoF and R456G missense hiPSC-CMs during differentiation shows an enrichment for cardiac genes.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53278-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>GATA6 ChIP-seq peaks in WT and GATA6 Mutant iPSCs and iPSC-CMs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53278-supp4-v2.xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Differential Genes Expressed in WT iPSC-CMs between day 4 and day 5 of differentiation.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53278-supp5-v2.xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Diminished ATAC peaks (≥2 fold) in day 4 GATA6 LoF and missense cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53278-supp6-v2.xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>DNA-binding motifs found in ≥2 fold diminished ATAC peaks in gene promoters (0–10 kb from TSS) of differentially expressed genes in day 4 GATA6 LoF and missense cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53278-supp7-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-53278-transrepform-v2.al.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Verzi</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>GATA6 ChIP-seq in differentiated cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM575227">GSM575227</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>de Santa Pau</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>GATA6 ChIP-seq</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1151694">GSM1151694</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Shivdasani</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><data-title>Genome-wide analyses of GATA6 occupancy and functions provide insights into its oncogenic mechanisms in human gastric cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51936">GSE51936</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Verzi</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>GATA6 ChIP-seq in proliferating cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM575226">GSM575226</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akerman</surname> <given-names>I</given-names></name><name><surname>Tu</surname> <given-names>Z</given-names></name><name><surname>Beucher</surname> <given-names>A</given-names></name><name><surname>Rolando</surname> <given-names>DMY</given-names></name><name><surname>Sauty-Colace</surname> <given-names>C</given-names></name><name><surname>Benazra</surname> <given-names>M</given-names></name><name><surname>Nakic</surname> <given-names>N</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Pasquali</surname> <given-names>L</given-names></name><name><surname>Moran</surname> <given-names>I</given-names></name><name><surname>Garcia-Hurtado</surname> <given-names>J</given-names></name><name><surname>Castro</surname> <given-names>N</given-names></name><name><surname>Gonzalez-Franco</surname> <given-names>R</given-names></name><name><surname>Stewart</surname> <given-names>AF</given-names></name><name><surname>Bonner</surname> <given-names>C</given-names></name><name><surname>Piemonti</surname> <given-names>L</given-names></name><name><surname>Berney</surname> <given-names>T</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Kerr-Conte</surname> <given-names>J</given-names></name><name><surname>Pattou</surname> <given-names>F</given-names></name><name><surname>Argmann</surname> <given-names>C</given-names></name><name><surname>Schadt</surname> <given-names>E</given-names></name><name><surname>Ravassard</surname> <given-names>P</given-names></name><name><surname>Ferrer</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Human pancreatic β cell lncRNAs control Cell-Specific regulatory networks</article-title><source>Cell Metabolism</source><volume>25</volume><fpage>400</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.11.016</pub-id><pub-id pub-id-type="pmid">28041957</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backs</surname> <given-names>J</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Control of cardiac growth by histone acetylation/deacetylation</article-title><source>Circulation Research</source><volume>98</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000197782.21444.8f</pub-id><pub-id pub-id-type="pmid">16397154</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basson</surname> <given-names>CT</given-names></name><name><surname>Bachinsky</surname> <given-names>DR</given-names></name><name><surname>Lin</surname> <given-names>RC</given-names></name><name><surname>Levi</surname> <given-names>T</given-names></name><name><surname>Elkins</surname> <given-names>JA</given-names></name><name><surname>Soults</surname> <given-names>J</given-names></name><name><surname>Grayzel</surname> <given-names>D</given-names></name><name><surname>Kroumpouzou</surname> <given-names>E</given-names></name><name><surname>Traill</surname> <given-names>TA</given-names></name><name><surname>Leblanc-Straceski</surname> <given-names>J</given-names></name><name><surname>Renault</surname> <given-names>B</given-names></name><name><surname>Kucherlapati</surname> <given-names>R</given-names></name><name><surname>J.G</surname> <given-names>S</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Mutations in human cause limb and cardiac malformation in Holt-Oram syndrome</article-title><source>Nature Genetics</source><volume>15</volume><fpage>30</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/ng0197-30</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname> <given-names>DL</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Kim</surname> <given-names>G</given-names></name><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Crystal structures of multiple GATA zinc fingers bound to DNA reveal new insights into DNA recognition and self-association by GATA</article-title><source>Journal of Molecular Biology</source><volume>381</volume><fpage>1292</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2008.06.072</pub-id><pub-id pub-id-type="pmid">18621058</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname> <given-names>DW</given-names></name><name><surname>Silberbach</surname> <given-names>GM</given-names></name><name><surname>Kavanaugh-McHugh</surname> <given-names>A</given-names></name><name><surname>Cottrill</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Riggs</surname> <given-names>S</given-names></name><name><surname>Smalls</surname> <given-names>O</given-names></name><name><surname>Johnson</surname> <given-names>MC</given-names></name><name><surname>Watson</surname> <given-names>MS</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name><name><surname>Plowden</surname> <given-names>J</given-names></name><name><surname>Kugler</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways</article-title><source>Journal of Clinical Investigation</source><volume>104</volume><fpage>1567</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1172/JCI8154</pub-id><pub-id pub-id-type="pmid">10587520</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouillet</surname> <given-names>P</given-names></name><name><surname>Sapin</surname> <given-names>V</given-names></name><name><surname>Chazaud</surname> <given-names>C</given-names></name><name><surname>Messaddeq</surname> <given-names>N</given-names></name><name><surname>Décimo</surname> <given-names>D</given-names></name><name><surname>Dollé</surname> <given-names>P</given-names></name><name><surname>Chambon</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Developmental expression pattern of Stra6, a retinoic acid-responsive gene encoding a new type of membrane protein</article-title><source>Mechanisms of Development</source><volume>63</volume><fpage>173</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/S0925-4773(97)00039-7</pub-id><pub-id pub-id-type="pmid">9203140</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brickner</surname> <given-names>ME</given-names></name><name><surname>Hillis</surname> <given-names>LD</given-names></name><name><surname>Lange</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Congenital heart disease in adults first of two parts</article-title><source>The New England Journal of Medicine</source><volume>342</volume><fpage>256</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1056/NEJM200001273420407</pub-id><pub-id pub-id-type="pmid">10648769</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruneau</surname> <given-names>BG</given-names></name><name><surname>Nemer</surname> <given-names>G</given-names></name><name><surname>Schmitt</surname> <given-names>JP</given-names></name><name><surname>Charron</surname> <given-names>F</given-names></name><name><surname>Robitaille</surname> <given-names>L</given-names></name><name><surname>Caron</surname> <given-names>S</given-names></name><name><surname>Conner</surname> <given-names>DA</given-names></name><name><surname>Gessler</surname> <given-names>M</given-names></name><name><surname>Nemer</surname> <given-names>M</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease</article-title><source>Cell</source><volume>106</volume><fpage>709</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00493-7</pub-id><pub-id pub-id-type="pmid">11572777</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckingham</surname> <given-names>M</given-names></name><name><surname>Meilhac</surname> <given-names>S</given-names></name><name><surname>Zaffran</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Building the mammalian heart from two sources of myocardial cells</article-title><source>Nature Reviews Genetics</source><volume>6</volume><fpage>826</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1038/nrg1710</pub-id><pub-id pub-id-type="pmid">16304598</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buenrostro</surname> <given-names>JD</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>Greenleaf</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Atac‐seq: a method for assaying chromatin accessibility genome‐wide</article-title><source>Current Protocols in Molecular Biology</source><volume>109</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/0471142727.mb2129s109</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrasco</surname> <given-names>M</given-names></name><name><surname>Delgado</surname> <given-names>I</given-names></name><name><surname>Soria</surname> <given-names>B</given-names></name><name><surname>Martín</surname> <given-names>F</given-names></name><name><surname>Rojas</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>GATA4 and GATA6 control mouse pancreas organogenesis</article-title><source>Journal of Clinical Investigation</source><volume>122</volume><fpage>3504</fpage><lpage>3515</lpage><pub-id pub-id-type="doi">10.1172/JCI63240</pub-id><pub-id pub-id-type="pmid">23006330</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname> <given-names>CS</given-names></name><name><surname>McKnight</surname> <given-names>KD</given-names></name><name><surname>Cox</surname> <given-names>KL</given-names></name><name><surname>Chang</surname> <given-names>AL</given-names></name><name><surname>Kim</surname> <given-names>SK</given-names></name><name><surname>Feldman</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Novel GATA6 mutations in patients with pancreatic agenesis and congenital heart malformations</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0118449</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0118449</pub-id><pub-id pub-id-type="pmid">25706805</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Chapman</surname> <given-names>B</given-names></name><name><surname>Kirchner</surname> <given-names>R</given-names></name><name><surname>Pantano</surname> <given-names>L</given-names></name><name><surname>Smet</surname> <given-names>MD</given-names></name><name><surname>Beltrame</surname> <given-names>L</given-names></name><name><surname>Khotiainsteva</surname> <given-names>T</given-names></name><name><surname>Naumenko</surname> <given-names>S</given-names></name><name><surname>Saveliev</surname> <given-names>V</given-names></name><name><surname>Guimera</surname> <given-names>RV</given-names></name><name><surname>Sytchev</surname> <given-names>I</given-names></name><name><surname>Kern</surname> <given-names>J</given-names></name><name><surname>Brueffer</surname> <given-names>C</given-names></name><name><surname>Carrasco</surname> <given-names>G</given-names></name><name><surname>Giovacchini</surname> <given-names>M</given-names></name><name><surname>Tang</surname> <given-names>P</given-names></name><name><surname>Ahdesmaki</surname> <given-names>M</given-names></name><name><surname>Kanwal</surname> <given-names>S</given-names></name><name><surname>Porter</surname> <given-names>JJ</given-names></name><name><surname>Möller</surname> <given-names>S</given-names></name><name><surname>Le</surname> <given-names>V</given-names></name><name><surname>Coman</surname> <given-names>A</given-names></name><name><surname>Svensson</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><source>Bcbio/bcbio-Nextgen: v1.2.3, Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://zenodo.org/record/3743344#.X4mP_3WFPeQ">https://zenodo.org/record/3743344#.X4mP_3WFPeQ</ext-link></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Clarke</surname> <given-names>OB</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Stowe</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>YK</given-names></name><name><surname>Assur</surname> <given-names>Z</given-names></name><name><surname>Cavalier</surname> <given-names>M</given-names></name><name><surname>Godoy-Ruiz</surname> <given-names>R</given-names></name><name><surname>von Alpen</surname> <given-names>DC</given-names></name><name><surname>Manzini</surname> <given-names>C</given-names></name><name><surname>Blaner</surname> <given-names>WS</given-names></name><name><surname>Frank</surname> <given-names>J</given-names></name><name><surname>Quadro</surname> <given-names>L</given-names></name><name><surname>Weber</surname> <given-names>DJ</given-names></name><name><surname>Shapiro</surname> <given-names>L</given-names></name><name><surname>Hendrickson</surname> <given-names>WA</given-names></name><name><surname>Mancia</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structure of the STRA6 receptor for retinol uptake</article-title><source>Science</source><volume>353</volume><elocation-id>aad8266</elocation-id><pub-id pub-id-type="doi">10.1126/science.aad8266</pub-id><pub-id pub-id-type="pmid">27563101</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coles</surname> <given-names>GL</given-names></name><name><surname>Ackerman</surname> <given-names>KG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Kif7 is required for the patterning and differentiation of the diaphragm in a model of syndromic congenital diaphragmatic hernia</article-title><source>PNAS</source><volume>110</volume><fpage>E1898</fpage><lpage>E1905</lpage><pub-id pub-id-type="doi">10.1073/pnas.1222797110</pub-id><pub-id pub-id-type="pmid">23650387</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname> <given-names>SJ</given-names></name><name><surname>Henderson</surname> <given-names>DJ</given-names></name><name><surname>Kirby</surname> <given-names>ML</given-names></name><name><surname>Anderson</surname> <given-names>RH</given-names></name><name><surname>Copp</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Development of a lethal congenital heart defect in the splotch (Pax3) mutant mouse</article-title><source>Cardiovascular Research</source><volume>36</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(97)00172-7</pub-id><pub-id pub-id-type="pmid">9463628</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corces</surname> <given-names>MR</given-names></name><name><surname>Trevino</surname> <given-names>AE</given-names></name><name><surname>Hamilton</surname> <given-names>EG</given-names></name><name><surname>Greenside</surname> <given-names>PG</given-names></name><name><surname>Sinnott-Armstrong</surname> <given-names>NA</given-names></name><name><surname>Vesuna</surname> <given-names>S</given-names></name><name><surname>Satpathy</surname> <given-names>AT</given-names></name><name><surname>Rubin</surname> <given-names>AJ</given-names></name><name><surname>Montine</surname> <given-names>KS</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Kathiria</surname> <given-names>A</given-names></name><name><surname>Cho</surname> <given-names>SW</given-names></name><name><surname>Mumbach</surname> <given-names>MR</given-names></name><name><surname>Carter</surname> <given-names>AC</given-names></name><name><surname>Kasowski</surname> <given-names>M</given-names></name><name><surname>Orloff</surname> <given-names>LA</given-names></name><name><surname>Risca</surname> <given-names>VI</given-names></name><name><surname>Kundaje</surname> <given-names>A</given-names></name><name><surname>Khavari</surname> <given-names>PA</given-names></name><name><surname>Montine</surname> <given-names>TJ</given-names></name><name><surname>Greenleaf</surname> <given-names>WJ</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues</article-title><source>Nature Methods</source><volume>14</volume><fpage>959</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4396</pub-id><pub-id pub-id-type="pmid">28846090</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Franco</surname> <given-names>E</given-names></name><name><surname>Shaw-Smith</surname> <given-names>C</given-names></name><name><surname>Flanagan</surname> <given-names>SE</given-names></name><name><surname>Shepherd</surname> <given-names>MH</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Ellard</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to Adult-Onset diabetes without exocrine insufficiency</article-title><source>Diabetes</source><volume>62</volume><fpage>993</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.2337/db12-0885</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLaughter</surname> <given-names>DM</given-names></name><name><surname>Bick</surname> <given-names>AG</given-names></name><name><surname>Wakimoto</surname> <given-names>H</given-names></name><name><surname>McKean</surname> <given-names>D</given-names></name><name><surname>Gorham</surname> <given-names>JM</given-names></name><name><surname>Kathiriya</surname> <given-names>IS</given-names></name><name><surname>Hinson</surname> <given-names>JT</given-names></name><name><surname>Homsy</surname> <given-names>J</given-names></name><name><surname>Gray</surname> <given-names>J</given-names></name><name><surname>Pu</surname> <given-names>W</given-names></name><name><surname>Bruneau</surname> <given-names>BG</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Single-Cell resolution of temporal gene expression during heart development</article-title><source>Developmental Cell</source><volume>39</volume><fpage>480</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2016.10.001</pub-id><pub-id pub-id-type="pmid">27840107</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>C</given-names></name><name><surname>Wei</surname> <given-names>P</given-names></name><name><surname>Jian</surname> <given-names>X</given-names></name><name><surname>Gibbs</surname> <given-names>R</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>2125</fpage><lpage>2137</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu733</pub-id><pub-id pub-id-type="pmid">25552646</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Haddad</surname> <given-names>M</given-names></name><name><surname>Notarnicola</surname> <given-names>C</given-names></name><name><surname>Evano</surname> <given-names>B</given-names></name><name><surname>El Khatib</surname> <given-names>N</given-names></name><name><surname>Blaquière</surname> <given-names>M</given-names></name><name><surname>Bonnieu</surname> <given-names>A</given-names></name><name><surname>Tajbakhsh</surname> <given-names>S</given-names></name><name><surname>Hugon</surname> <given-names>G</given-names></name><name><surname>Vernus</surname> <given-names>B</given-names></name><name><surname>Mercier</surname> <given-names>J</given-names></name><name><surname>Carnac</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Retinoic acid maintains human skeletal muscle progenitor cells in an immature state</article-title><source>Cellular and Molecular Life Sciences</source><volume>74</volume><fpage>1923</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2445-1</pub-id><pub-id pub-id-type="pmid">28025671</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahed</surname> <given-names>AC</given-names></name><name><surname>Gelb</surname> <given-names>BD</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genetics of congenital heart disease: the glass half empty</article-title><source>Circulation Research</source><volume>112</volume><fpage>707</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.112.300853</pub-id><pub-id pub-id-type="pmid">23410880</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname> <given-names>JB</given-names></name><name><surname>Pulakanti</surname> <given-names>K</given-names></name><name><surname>Rao</surname> <given-names>S</given-names></name><name><surname>Duncan</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GATA6 is essential for endoderm formation from human pluripotent stem cells</article-title><source>Biology Open</source><volume>6</volume><fpage>1084</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1242/bio.026120</pub-id><pub-id pub-id-type="pmid">28606935</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>N</given-names></name><name><surname>LeLay</surname> <given-names>J</given-names></name><name><surname>Vatamaniuk</surname> <given-names>MZ</given-names></name><name><surname>Rieck</surname> <given-names>S</given-names></name><name><surname>Friedman</surname> <given-names>JR</given-names></name><name><surname>Kaestner</surname> <given-names>KH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development</article-title><source>Genes &amp; Development</source><volume>22</volume><fpage>3435</fpage><lpage>3448</lpage><pub-id pub-id-type="doi">10.1101/gad.1752608</pub-id><pub-id pub-id-type="pmid">19141476</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname> <given-names>V</given-names></name><name><surname>Kathiriya</surname> <given-names>IS</given-names></name><name><surname>Barnes</surname> <given-names>R</given-names></name><name><surname>Schluterman</surname> <given-names>MK</given-names></name><name><surname>King</surname> <given-names>IN</given-names></name><name><surname>Butler</surname> <given-names>CA</given-names></name><name><surname>Rothrock</surname> <given-names>CR</given-names></name><name><surname>Eapen</surname> <given-names>RS</given-names></name><name><surname>Hirayama-Yamada</surname> <given-names>K</given-names></name><name><surname>Joo</surname> <given-names>K</given-names></name><name><surname>Matsuoka</surname> <given-names>R</given-names></name><name><surname>Cohen</surname> <given-names>JC</given-names></name><name><surname>Srivastava</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5</article-title><source>Nature</source><volume>424</volume><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/nature01827</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelb</surname> <given-names>B</given-names></name><name><surname>Brueckner</surname> <given-names>M</given-names></name><name><surname>Chung</surname> <given-names>W</given-names></name><name><surname>Goldmuntz</surname> <given-names>E</given-names></name><name><surname>Kaltman</surname> <given-names>J</given-names></name><name><surname>Kaski</surname> <given-names>JP</given-names></name><name><surname>Kim</surname> <given-names>R</given-names></name><name><surname>Kline</surname> <given-names>J</given-names></name><name><surname>Mercer-Rosa</surname> <given-names>L</given-names></name><name><surname>Porter</surname> <given-names>G</given-names></name><name><surname>Roberts</surname> <given-names>A</given-names></name><name><surname>Rosenberg</surname> <given-names>E</given-names></name><name><surname>Seiden</surname> <given-names>H</given-names></name><name><surname>Seidman</surname> <given-names>C</given-names></name><name><surname>Sleeper</surname> <given-names>L</given-names></name><name><surname>Tennstedt</surname> <given-names>S</given-names></name><name><surname>Kaltman</surname> <given-names>J</given-names></name><name><surname>Schramm</surname> <given-names>C</given-names></name><name><surname>Burns</surname> <given-names>K</given-names></name><name><surname>Pearson</surname> <given-names>G</given-names></name><name><surname>Rosenberg</surname> <given-names>E</given-names></name><collab>Pediatric Cardiac Genomics Consortium</collab></person-group><year iso-8601-date="2013">2013</year><article-title>The congenital heart disease genetic network study: rationale, design, and early results</article-title><source>Circulation Research</source><volume>112</volume><fpage>698</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.300297</pub-id><pub-id pub-id-type="pmid">23410879</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerrish</surname> <given-names>K</given-names></name><name><surname>Cissell</surname> <given-names>MA</given-names></name><name><surname>Stein</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The role of hepatic nuclear factor 1 alpha and <italic>PDX-1</italic> in transcriptional regulation of the <italic>pdx-1</italic> gene</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>47775</fpage><lpage>47784</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109244200</pub-id><pub-id pub-id-type="pmid">11590182</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gharibeh</surname> <given-names>L</given-names></name><name><surname>Komati</surname> <given-names>H</given-names></name><name><surname>Bossé</surname> <given-names>Y</given-names></name><name><surname>Boodhwani</surname> <given-names>M</given-names></name><name><surname>Heydarpour</surname> <given-names>M</given-names></name><name><surname>Fortier</surname> <given-names>M</given-names></name><name><surname>Hassanzadeh</surname> <given-names>R</given-names></name><name><surname>Ngu</surname> <given-names>J</given-names></name><name><surname>Mathieu</surname> <given-names>P</given-names></name><name><surname>Body</surname> <given-names>S</given-names></name><name><surname>Nemer</surname> <given-names>M</given-names></name><collab>Bicuspid Aortic Valve Consortium</collab></person-group><year iso-8601-date="2018">2018</year><article-title>GATA6 regulates aortic valve remodeling, and its haploinsufficiency leads to Right-Left type bicuspid aortic valve</article-title><source>Circulation</source><volume>138</volume><fpage>1025</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.029506</pub-id><pub-id pub-id-type="pmid">29567669</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golzio</surname> <given-names>C</given-names></name><name><surname>Martinovic-Bouriel</surname> <given-names>J</given-names></name><name><surname>Thomas</surname> <given-names>S</given-names></name><name><surname>Mougou-Zrelli</surname> <given-names>S</given-names></name><name><surname>Grattagliano-Bessieres</surname> <given-names>B</given-names></name><name><surname>Bonniere</surname> <given-names>M</given-names></name><name><surname>Delahaye</surname> <given-names>S</given-names></name><name><surname>Munnich</surname> <given-names>A</given-names></name><name><surname>Encha-Razavi</surname> <given-names>F</given-names></name><name><surname>Lyonnet</surname> <given-names>S</given-names></name><name><surname>Vekemans</surname> <given-names>M</given-names></name><name><surname>Attie-Bitach</surname> <given-names>T</given-names></name><name><surname>Etchevers</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Matthew-Wood syndrome is caused by truncating mutations in the retinol-binding protein receptor gene STRA6</article-title><source>The American Journal of Human Genetics</source><volume>80</volume><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1086/518177</pub-id><pub-id pub-id-type="pmid">17503335</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname> <given-names>PD</given-names></name><name><surname>Pierce</surname> <given-names>SA</given-names></name><name><surname>Sims</surname> <given-names>RJ</given-names></name><name><surname>Yamagishi</surname> <given-names>H</given-names></name><name><surname>Weihe</surname> <given-names>EK</given-names></name><name><surname>Harriss</surname> <given-names>JV</given-names></name><name><surname>Maika</surname> <given-names>SD</given-names></name><name><surname>Kuziel</surname> <given-names>WA</given-names></name><name><surname>King</surname> <given-names>HL</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name><name><surname>Nakagawa</surname> <given-names>O</given-names></name><name><surname>Srivastava</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis</article-title><source>Nature Genetics</source><volume>31</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/ng866</pub-id><pub-id pub-id-type="pmid">11923873</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinz</surname> <given-names>S</given-names></name><name><surname>Benner</surname> <given-names>C</given-names></name><name><surname>Spann</surname> <given-names>N</given-names></name><name><surname>Bertolino</surname> <given-names>E</given-names></name><name><surname>Lin</surname> <given-names>YC</given-names></name><name><surname>Laslo</surname> <given-names>P</given-names></name><name><surname>Cheng</surname> <given-names>JX</given-names></name><name><surname>Murre</surname> <given-names>C</given-names></name><name><surname>Singh</surname> <given-names>H</given-names></name><name><surname>Glass</surname> <given-names>CK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities</article-title><source>Molecular Cell</source><volume>38</volume><fpage>576</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.004</pub-id><pub-id pub-id-type="pmid">20513432</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiroi</surname> <given-names>Y</given-names></name><name><surname>Kudoh</surname> <given-names>S</given-names></name><name><surname>Monzen</surname> <given-names>K</given-names></name><name><surname>Ikeda</surname> <given-names>Y</given-names></name><name><surname>Yazaki</surname> <given-names>Y</given-names></name><name><surname>Nagai</surname> <given-names>R</given-names></name><name><surname>Komuro</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation</article-title><source>Nature Genetics</source><volume>28</volume><fpage>276</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1038/90123</pub-id><pub-id pub-id-type="pmid">11431700</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homsy</surname> <given-names>J</given-names></name><name><surname>Zaidi</surname> <given-names>S</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Ware</surname> <given-names>JS</given-names></name><name><surname>Samocha</surname> <given-names>KE</given-names></name><name><surname>Karczewski</surname> <given-names>KJ</given-names></name><name><surname>DePalma</surname> <given-names>SR</given-names></name><name><surname>McKean</surname> <given-names>D</given-names></name><name><surname>Wakimoto</surname> <given-names>H</given-names></name><name><surname>Gorham</surname> <given-names>J</given-names></name><name><surname>Jin</surname> <given-names>SC</given-names></name><name><surname>Deanfield</surname> <given-names>J</given-names></name><name><surname>Giardini</surname> <given-names>A</given-names></name><name><surname>Porter</surname> <given-names>GA</given-names></name><name><surname>Kim</surname> <given-names>R</given-names></name><name><surname>Bilguvar</surname> <given-names>K</given-names></name><name><surname>López-Giráldez</surname> <given-names>F</given-names></name><name><surname>Tikhonova</surname> <given-names>I</given-names></name><name><surname>Mane</surname> <given-names>S</given-names></name><name><surname>Romano-Adesman</surname> <given-names>A</given-names></name><name><surname>Qi</surname> <given-names>H</given-names></name><name><surname>Vardarajan</surname> <given-names>B</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Daly</surname> <given-names>M</given-names></name><name><surname>Roberts</surname> <given-names>AE</given-names></name><name><surname>Russell</surname> <given-names>MW</given-names></name><name><surname>Mital</surname> <given-names>S</given-names></name><name><surname>Newburger</surname> <given-names>JW</given-names></name><name><surname>Gaynor</surname> <given-names>JW</given-names></name><name><surname>Breitbart</surname> <given-names>RE</given-names></name><name><surname>Iossifov</surname> <given-names>I</given-names></name><name><surname>Ronemus</surname> <given-names>M</given-names></name><name><surname>Sanders</surname> <given-names>SJ</given-names></name><name><surname>Kaltman</surname> <given-names>JR</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name><name><surname>Brueckner</surname> <given-names>M</given-names></name><name><surname>Gelb</surname> <given-names>BD</given-names></name><name><surname>Goldmuntz</surname> <given-names>E</given-names></name><name><surname>Lifton</surname> <given-names>RP</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name><name><surname>Chung</surname> <given-names>WK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies</article-title><source>Science</source><volume>350</volume><fpage>1262</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1126/science.aac9396</pub-id><pub-id pub-id-type="pmid">26785492</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>D</given-names></name><name><surname>Chen</surname> <given-names>SW</given-names></name><name><surname>Gudas</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Analysis of two distinct retinoic acid response elements in the homeobox gene Hoxb1 in transgenic mice</article-title><source>Developmental Dynamics</source><volume>223</volume><fpage>353</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1002/dvdy.10057</pub-id><pub-id pub-id-type="pmid">11891985</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iguchi</surname> <given-names>H</given-names></name><name><surname>Ikeda</surname> <given-names>Y</given-names></name><name><surname>Okamura</surname> <given-names>M</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Urashima</surname> <given-names>Y</given-names></name><name><surname>Ohguchi</surname> <given-names>H</given-names></name><name><surname>Takayasu</surname> <given-names>S</given-names></name><name><surname>Kojima</surname> <given-names>N</given-names></name><name><surname>Iwasaki</surname> <given-names>S</given-names></name><name><surname>Ohashi</surname> <given-names>R</given-names></name><name><surname>Jiang</surname> <given-names>S</given-names></name><name><surname>Hasegawa</surname> <given-names>G</given-names></name><name><surname>Ioka</surname> <given-names>RX</given-names></name><name><surname>Magoori</surname> <given-names>K</given-names></name><name><surname>Sumi</surname> <given-names>K</given-names></name><name><surname>Maejima</surname> <given-names>T</given-names></name><name><surname>Uchida</surname> <given-names>A</given-names></name><name><surname>Naito</surname> <given-names>M</given-names></name><name><surname>Osborne</surname> <given-names>TF</given-names></name><name><surname>Yanagisawa</surname> <given-names>M</given-names></name><name><surname>Yamamoto</surname> <given-names>TT</given-names></name><name><surname>Kodama</surname> <given-names>T</given-names></name><name><surname>Sakai</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>SOX6 attenuates glucose-stimulated insulin secretion by repressing PDX1 transcriptional activity and is down-regulated in hyperinsulinemic obese mice</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>37669</fpage><lpage>37680</lpage><pub-id pub-id-type="doi">10.1074/jbc.M505392200</pub-id><pub-id pub-id-type="pmid">16148004</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaurena</surname> <given-names>MB</given-names></name><name><surname>Juraver-Geslin</surname> <given-names>H</given-names></name><name><surname>Devotta</surname> <given-names>A</given-names></name><name><surname>Saint-Jeannet</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Zic1 controls placode progenitor formation non-cell autonomously by regulating retinoic acid production and transport</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7476</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8476</pub-id><pub-id pub-id-type="pmid">26101153</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The lncRNA DEANR1 facilitates human endoderm differentiation by activating FOXA2 expression</article-title><source>Cell Reports</source><volume>11</volume><fpage>137</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.03.008</pub-id><pub-id pub-id-type="pmid">25843708</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>SC</given-names></name><name><surname>Homsy</surname> <given-names>J</given-names></name><name><surname>Zaidi</surname> <given-names>S</given-names></name><name><surname>Lu</surname> <given-names>Q</given-names></name><name><surname>Morton</surname> <given-names>S</given-names></name><name><surname>DePalma</surname> <given-names>SR</given-names></name><name><surname>Zeng</surname> <given-names>X</given-names></name><name><surname>Qi</surname> <given-names>H</given-names></name><name><surname>Chang</surname> <given-names>W</given-names></name><name><surname>Sierant</surname> <given-names>MC</given-names></name><name><surname>Hung</surname> <given-names>WC</given-names></name><name><surname>Haider</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Knight</surname> <given-names>J</given-names></name><name><surname>Bjornson</surname> <given-names>RD</given-names></name><name><surname>Castaldi</surname> <given-names>C</given-names></name><name><surname>Tikhonoa</surname> <given-names>IR</given-names></name><name><surname>Bilguvar</surname> <given-names>K</given-names></name><name><surname>Mane</surname> <given-names>SM</given-names></name><name><surname>Sanders</surname> <given-names>SJ</given-names></name><name><surname>Mital</surname> <given-names>S</given-names></name><name><surname>Russell</surname> <given-names>MW</given-names></name><name><surname>Gaynor</surname> <given-names>JW</given-names></name><name><surname>Deanfield</surname> <given-names>J</given-names></name><name><surname>Giardini</surname> <given-names>A</given-names></name><name><surname>Porter</surname> <given-names>GA</given-names></name><name><surname>Srivastava</surname> <given-names>D</given-names></name><name><surname>Lo</surname> <given-names>CW</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Watkins</surname> <given-names>WS</given-names></name><name><surname>Yandell</surname> <given-names>M</given-names></name><name><surname>Yost</surname> <given-names>HJ</given-names></name><name><surname>Tristani-Firouzi</surname> <given-names>M</given-names></name><name><surname>Newburger</surname> <given-names>JW</given-names></name><name><surname>Roberts</surname> <given-names>AE</given-names></name><name><surname>Kim</surname> <given-names>R</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Kaltman</surname> <given-names>JR</given-names></name><name><surname>Goldmuntz</surname> <given-names>E</given-names></name><name><surname>Chung</surname> <given-names>WK</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name><name><surname>Gelb</surname> <given-names>BD</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name><name><surname>Lifton</surname> <given-names>RP</given-names></name><name><surname>Brueckner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands</article-title><source>Nature Genetics</source><volume>49</volume><fpage>1593</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1038/ng.3970</pub-id><pub-id pub-id-type="pmid">28991257</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kardon</surname> <given-names>G</given-names></name><name><surname>Ackerman</surname> <given-names>KG</given-names></name><name><surname>McCulley</surname> <given-names>DJ</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Wynn</surname> <given-names>J</given-names></name><name><surname>Shang</surname> <given-names>L</given-names></name><name><surname>Bogenschutz</surname> <given-names>E</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Chung</surname> <given-names>WK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Congenital diaphragmatic hernias: from genes to mechanisms to therapies</article-title><source>Disease Models &amp; Mechanisms</source><volume>10</volume><fpage>955</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1242/dmm.028365</pub-id><pub-id pub-id-type="pmid">28768736</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The second heart field</article-title><source>Current Topics in Developmental Biology</source><volume>100</volume><fpage>33</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-387786-4.00002-6</pub-id><pub-id pub-id-type="pmid">22449840</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodo</surname> <given-names>K</given-names></name><name><surname>Nishizawa</surname> <given-names>T</given-names></name><name><surname>Furutani</surname> <given-names>M</given-names></name><name><surname>Arai</surname> <given-names>S</given-names></name><name><surname>Yamamura</surname> <given-names>E</given-names></name><name><surname>Joo</surname> <given-names>K</given-names></name><name><surname>Takahashi</surname> <given-names>T</given-names></name><name><surname>Matsuoka</surname> <given-names>R</given-names></name><name><surname>Yamagishi</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling</article-title><source>PNAS</source><volume>106</volume><fpage>13933</fpage><lpage>13938</lpage><pub-id pub-id-type="doi">10.1073/pnas.0904744106</pub-id><pub-id pub-id-type="pmid">19666519</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laforest</surname> <given-names>B</given-names></name><name><surname>Nemer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>GATA5 interacts with GATA4 and GATA6 in outflow tract development</article-title><source>Developmental Biology</source><volume>358</volume><fpage>368</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2011.07.037</pub-id><pub-id pub-id-type="pmid">21839733</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurent</surname> <given-names>F</given-names></name><name><surname>Girdziusaite</surname> <given-names>A</given-names></name><name><surname>Gamart</surname> <given-names>J</given-names></name><name><surname>Barozzi</surname> <given-names>I</given-names></name><name><surname>Osterwalder</surname> <given-names>M</given-names></name><name><surname>Akiyama</surname> <given-names>JA</given-names></name><name><surname>Lincoln</surname> <given-names>J</given-names></name><name><surname>Lopez-Rios</surname> <given-names>J</given-names></name><name><surname>Visel</surname> <given-names>A</given-names></name><name><surname>Zuniga</surname> <given-names>A</given-names></name><name><surname>Zeller</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>HAND2 target gene regulatory networks control atrioventricular canal and cardiac valve development</article-title><source>Cell Reports</source><volume>19</volume><fpage>1602</fpage><lpage>1613</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.05.004</pub-id><pub-id pub-id-type="pmid">28538179</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Park</surname> <given-names>IH</given-names></name><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>JB</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Daley</surname> <given-names>GQ</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Church</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells</article-title><source>PLOS Genetics</source><volume>5</volume><elocation-id>e1000718</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000718</pub-id><pub-id pub-id-type="pmid">19911041</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>K</given-names></name><name><surname>Cho</surname> <given-names>H</given-names></name><name><surname>Rickert</surname> <given-names>RW</given-names></name><name><surname>Li</surname> <given-names>QV</given-names></name><name><surname>Pulecio</surname> <given-names>J</given-names></name><name><surname>Leslie</surname> <given-names>CS</given-names></name><name><surname>Huangfu</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>FOXA2 is required for enhancer priming during pancreatic differentiation</article-title><source>Cell Reports</source><volume>28</volume><fpage>382</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.06.034</pub-id><pub-id pub-id-type="pmid">31291575</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepore</surname> <given-names>JJ</given-names></name><name><surname>Mericko</surname> <given-names>PA</given-names></name><name><surname>Cheng</surname> <given-names>L</given-names></name><name><surname>Lu</surname> <given-names>MM</given-names></name><name><surname>Morrisey</surname> <given-names>EE</given-names></name><name><surname>Parmacek</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>GATA-6 regulates semaphorin 3C and is required in cardiac neural crest for cardiovascular morphogenesis</article-title><source>Journal of Clinical Investigation</source><volume>116</volume><fpage>929</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1172/JCI27363</pub-id><pub-id pub-id-type="pmid">16557299</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Bian</surname> <given-names>YH</given-names></name><name><surname>Rotllant</surname> <given-names>P</given-names></name><name><surname>Shen</surname> <given-names>T</given-names></name><name><surname>Chu</surname> <given-names>W</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Schneider</surname> <given-names>M</given-names></name><name><surname>Du</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Smyd1b_tv1, a key regulator of sarcomere assembly, is localized on the M-line of skeletal muscle fibers</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e28524</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0028524</pub-id><pub-id pub-id-type="pmid">22174829</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Xu</surname> <given-names>A</given-names></name><name><surname>Sim</surname> <given-names>S</given-names></name><name><surname>Priest</surname> <given-names>JR</given-names></name><name><surname>Tian</surname> <given-names>X</given-names></name><name><surname>Khan</surname> <given-names>T</given-names></name><name><surname>Quertermous</surname> <given-names>T</given-names></name><name><surname>Zhou</surname> <given-names>B</given-names></name><name><surname>Tsao</surname> <given-names>PS</given-names></name><name><surname>Quake</surname> <given-names>SR</given-names></name><name><surname>Wu</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transcriptomic profiling maps anatomically patterned subpopulations among single embryonic cardiac cells</article-title><source>Developmental Cell</source><volume>39</volume><fpage>491</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2016.10.014</pub-id><pub-id pub-id-type="pmid">27840109</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>Q</given-names></name><name><surname>Srivastava</surname> <given-names>D</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>A transcriptional pathway for cardiac development</article-title><conf-name>Cold Spring Harbor Symposia on Quantitative Biology</conf-name><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">9598375</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litviňuková</surname> <given-names>M</given-names></name><name><surname>Talavera-López</surname> <given-names>C</given-names></name><name><surname>Maatz</surname> <given-names>H</given-names></name><name><surname>Reichart</surname> <given-names>D</given-names></name><name><surname>Worth</surname> <given-names>CL</given-names></name><name><surname>Lindberg</surname> <given-names>EL</given-names></name><name><surname>Kanda</surname> <given-names>M</given-names></name><name><surname>Polanski</surname> <given-names>K</given-names></name><name><surname>Heinig</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>M</given-names></name><name><surname>Nadelmann</surname> <given-names>ER</given-names></name><name><surname>Roberts</surname> <given-names>K</given-names></name><name><surname>Tuck</surname> <given-names>L</given-names></name><name><surname>Fasouli</surname> <given-names>ES</given-names></name><name><surname>DeLaughter</surname> <given-names>DM</given-names></name><name><surname>McDonough</surname> <given-names>B</given-names></name><name><surname>Wakimoto</surname> <given-names>H</given-names></name><name><surname>Gorham</surname> <given-names>JM</given-names></name><name><surname>Samari</surname> <given-names>S</given-names></name><name><surname>Mahbubani</surname> <given-names>KT</given-names></name><name><surname>Saeb-Parsy</surname> <given-names>K</given-names></name><name><surname>Patone</surname> <given-names>G</given-names></name><name><surname>Boyle</surname> <given-names>JJ</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Viveiros</surname> <given-names>A</given-names></name><name><surname>Oudit</surname> <given-names>GY</given-names></name><name><surname>Bayraktar</surname> <given-names>O</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name><name><surname>Noseda</surname> <given-names>M</given-names></name><name><surname>Hubner</surname> <given-names>N</given-names></name><name><surname>Teichmann</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cells of the adult human heart</article-title><source>Nature</source><volume>4</volume><elocation-id>2797</elocation-id><pub-id pub-id-type="doi">10.1038/s41586-020-2797-4</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Losa</surname> <given-names>M</given-names></name><name><surname>Latorre</surname> <given-names>V</given-names></name><name><surname>Andrabi</surname> <given-names>M</given-names></name><name><surname>Ladam</surname> <given-names>F</given-names></name><name><surname>Sagerström</surname> <given-names>C</given-names></name><name><surname>Novoa</surname> <given-names>A</given-names></name><name><surname>Zarrineh</surname> <given-names>P</given-names></name><name><surname>Bridoux</surname> <given-names>L</given-names></name><name><surname>Hanley</surname> <given-names>NA</given-names></name><name><surname>Mallo</surname> <given-names>M</given-names></name><name><surname>Bobola</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A tissue-specific, Gata6-driven transcriptional program instructs remodeling of the mature arterial tree</article-title><source>eLife</source><volume>6</volume><elocation-id>e31362</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.31362</pub-id><pub-id pub-id-type="pmid">28952437</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luna-Zurita</surname> <given-names>L</given-names></name><name><surname>Stirnimann</surname> <given-names>CU</given-names></name><name><surname>Glatt</surname> <given-names>S</given-names></name><name><surname>Kaynak</surname> <given-names>BL</given-names></name><name><surname>Thomas</surname> <given-names>S</given-names></name><name><surname>Baudin</surname> <given-names>F</given-names></name><name><surname>Samee</surname> <given-names>MAH</given-names></name><name><surname>He</surname> <given-names>D</given-names></name><name><surname>Small</surname> <given-names>EM</given-names></name><name><surname>Mileikovsky</surname> <given-names>M</given-names></name><name><surname>Nagy</surname> <given-names>A</given-names></name><name><surname>Holloway</surname> <given-names>AK</given-names></name><name><surname>Pollard</surname> <given-names>KS</given-names></name><name><surname>Müller</surname> <given-names>CW</given-names></name><name><surname>Bruneau</surname> <given-names>BG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complex interdependence regulates heterotypic transcription factor distribution and coordinates cardiogenesis</article-title><source>Cell</source><volume>164</volume><fpage>999</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.01.004</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magli</surname> <given-names>A</given-names></name><name><surname>Baik</surname> <given-names>J</given-names></name><name><surname>Pota</surname> <given-names>P</given-names></name><name><surname>Cordero</surname> <given-names>CO</given-names></name><name><surname>Kwak</surname> <given-names>IY</given-names></name><name><surname>Garry</surname> <given-names>DJ</given-names></name><name><surname>Love</surname> <given-names>PE</given-names></name><name><surname>Dynlacht</surname> <given-names>BD</given-names></name><name><surname>Perlingeiro</surname> <given-names>RCR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pax3 cooperates with Ldb1 to direct local chromosome architecture during myogenic lineage specification</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2316</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10318-6</pub-id><pub-id pub-id-type="pmid">31127120</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maitra</surname> <given-names>M</given-names></name><name><surname>Schluterman</surname> <given-names>MK</given-names></name><name><surname>Nichols</surname> <given-names>HA</given-names></name><name><surname>Richardson</surname> <given-names>JA</given-names></name><name><surname>Lo</surname> <given-names>CW</given-names></name><name><surname>Srivastava</surname> <given-names>D</given-names></name><name><surname>Garg</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Interaction of Gata4 and Gata6 with Tbx5 is critical for normal cardiac development</article-title><source>Developmental Biology</source><volume>326</volume><fpage>368</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2008.11.004</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maitra</surname> <given-names>M</given-names></name><name><surname>Koenig</surname> <given-names>SN</given-names></name><name><surname>Srivastava</surname> <given-names>D</given-names></name><name><surname>Garg</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Identification of GATA6 sequence variants in patients with congenital heart defects</article-title><source>Pediatric Research</source><volume>68</volume><fpage>281</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1203/PDR.0b013e3181ed17e4</pub-id><pub-id pub-id-type="pmid">20581743</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makki</surname> <given-names>N</given-names></name><name><surname>Capecchi</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Identification of novel Hoxa1 downstream targets regulating hindbrain, neural crest and inner ear development</article-title><source>Developmental Biology</source><volume>357</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2011.06.042</pub-id><pub-id pub-id-type="pmid">21784065</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marino</surname> <given-names>BS</given-names></name><name><surname>Lipkin</surname> <given-names>PH</given-names></name><name><surname>Newburger</surname> <given-names>JW</given-names></name><name><surname>Peacock</surname> <given-names>G</given-names></name><name><surname>Gerdes</surname> <given-names>M</given-names></name><name><surname>Gaynor</surname> <given-names>JW</given-names></name><name><surname>Mussatto</surname> <given-names>KA</given-names></name><name><surname>Uzark</surname> <given-names>K</given-names></name><name><surname>Goldberg</surname> <given-names>CS</given-names></name><name><surname>Johnson</surname> <given-names>WH</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Smith</surname> <given-names>SE</given-names></name><name><surname>Bellinger</surname> <given-names>DC</given-names></name><name><surname>Mahle</surname> <given-names>WT</given-names></name><collab>American Heart Association Congenital Heart Defects Committee, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, and Stroke Council</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the american heart association</article-title><source>Circulation</source><volume>126</volume><fpage>1143</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1161/CIR.0b013e318265ee8a</pub-id><pub-id pub-id-type="pmid">22851541</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Morales</surname> <given-names>PL</given-names></name><name><surname>Diez del Corral</surname> <given-names>R</given-names></name><name><surname>Olivera-Martínez</surname> <given-names>I</given-names></name><name><surname>Quiroga</surname> <given-names>AC</given-names></name><name><surname>Das</surname> <given-names>RM</given-names></name><name><surname>Barbas</surname> <given-names>JA</given-names></name><name><surname>Storey</surname> <given-names>KG</given-names></name><name><surname>Morales</surname> <given-names>AV</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>FGF and retinoic acid activity gradients control the timing of neural crest cell emigration in the trunk</article-title><source>Journal of Cell Biology</source><volume>194</volume><fpage>489</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1083/jcb.201011077</pub-id><pub-id pub-id-type="pmid">21807879</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname> <given-names>A</given-names></name><name><surname>Hanna</surname> <given-names>M</given-names></name><name><surname>Banks</surname> <given-names>E</given-names></name><name><surname>Sivachenko</surname> <given-names>A</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Kernytsky</surname> <given-names>A</given-names></name><name><surname>Garimella</surname> <given-names>K</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Daly</surname> <given-names>M</given-names></name><name><surname>DePristo</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title><source>Genome Research</source><volume>20</volume><fpage>1297</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id><pub-id pub-id-type="pmid">20644199</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molkentin</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The zinc finger-containing transcription factors GATA-4, -5, and -6. ubiquitously expressed regulators of tissue-specific gene expression</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>38949</fpage><lpage>38952</lpage><pub-id pub-id-type="doi">10.1074/jbc.R000029200</pub-id><pub-id pub-id-type="pmid">11042222</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrisey</surname> <given-names>EE</given-names></name><name><surname>Ip</surname> <given-names>HS</given-names></name><name><surname>Lu</surname> <given-names>MM</given-names></name><name><surname>Parmacek</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>GATA-6: a zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm</article-title><source>Developmental Biology</source><volume>177</volume><fpage>309</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1006/dbio.1996.0165</pub-id><pub-id pub-id-type="pmid">8660897</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrisey</surname> <given-names>EE</given-names></name><name><surname>Tang</surname> <given-names>Z</given-names></name><name><surname>Sigrist</surname> <given-names>K</given-names></name><name><surname>Lu</surname> <given-names>MM</given-names></name><name><surname>Jiang</surname> <given-names>F</given-names></name><name><surname>Ip</surname> <given-names>HS</given-names></name><name><surname>Parmacek</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo</article-title><source>Genes &amp; Development</source><volume>12</volume><fpage>3579</fpage><lpage>3590</lpage><pub-id pub-id-type="doi">10.1101/gad.12.22.3579</pub-id><pub-id pub-id-type="pmid">9832509</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasutto</surname> <given-names>F</given-names></name><name><surname>Sticht</surname> <given-names>H</given-names></name><name><surname>Hammersen</surname> <given-names>G</given-names></name><name><surname>Gillessen-Kaesbach</surname> <given-names>G</given-names></name><name><surname>Fitzpatrick</surname> <given-names>DR</given-names></name><name><surname>Nürnberg</surname> <given-names>G</given-names></name><name><surname>Brasch</surname> <given-names>F</given-names></name><name><surname>Schirmer-Zimmermann</surname> <given-names>H</given-names></name><name><surname>Tolmie</surname> <given-names>JL</given-names></name><name><surname>Chitayat</surname> <given-names>D</given-names></name><name><surname>Houge</surname> <given-names>G</given-names></name><name><surname>Fernández-Martínez</surname> <given-names>L</given-names></name><name><surname>Keating</surname> <given-names>S</given-names></name><name><surname>Mortier</surname> <given-names>G</given-names></name><name><surname>Hennekam</surname> <given-names>RC</given-names></name><name><surname>von der Wense</surname> <given-names>A</given-names></name><name><surname>Slavotinek</surname> <given-names>A</given-names></name><name><surname>Meinecke</surname> <given-names>P</given-names></name><name><surname>Bitoun</surname> <given-names>P</given-names></name><name><surname>Becker</surname> <given-names>C</given-names></name><name><surname>Nürnberg</surname> <given-names>P</given-names></name><name><surname>Reis</surname> <given-names>A</given-names></name><name><surname>Rauch</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung Hypoplasia, and mental retardation</article-title><source>The American Journal of Human Genetics</source><volume>80</volume><fpage>550</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1086/512203</pub-id><pub-id pub-id-type="pmid">17273977</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perl</surname> <given-names>E</given-names></name><name><surname>Waxman</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Reiterative mechanisms of retinoic acid signaling during vertebrate heart development</article-title><source>Journal of Developmental Biology</source><volume>7</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.3390/jdb7020011</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potthoff</surname> <given-names>MJ</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>MEF2: a central regulator of diverse developmental programs</article-title><source>Development</source><volume>134</volume><fpage>4131</fpage><lpage>4140</lpage><pub-id pub-id-type="doi">10.1242/dev.008367</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname> <given-names>MS</given-names></name><name><surname>Jobling</surname> <given-names>R</given-names></name><name><surname>Chaturvedi</surname> <given-names>RR</given-names></name><name><surname>Manshaei</surname> <given-names>R</given-names></name><name><surname>Costain</surname> <given-names>G</given-names></name><name><surname>Heung</surname> <given-names>T</given-names></name><name><surname>Curtis</surname> <given-names>M</given-names></name><name><surname>Hosseini</surname> <given-names>SM</given-names></name><name><surname>Liston</surname> <given-names>E</given-names></name><name><surname>Lowther</surname> <given-names>C</given-names></name><name><surname>Oechslin</surname> <given-names>E</given-names></name><name><surname>Sticht</surname> <given-names>H</given-names></name><name><surname>Thiruvahindrapuram</surname> <given-names>B</given-names></name><name><surname>Mil</surname> <given-names>SV</given-names></name><name><surname>Wald</surname> <given-names>RM</given-names></name><name><surname>Walker</surname> <given-names>S</given-names></name><name><surname>Marshall</surname> <given-names>CR</given-names></name><name><surname>Silversides</surname> <given-names>CK</given-names></name><name><surname>Scherer</surname> <given-names>SW</given-names></name><name><surname>Kim</surname> <given-names>RH</given-names></name><name><surname>Bassett</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Haploinsufficiency of vascular endothelial growth factor related signaling genes is associated with tetralogy of fallot</article-title><source>Genetics in Medicine</source><volume>21</volume><fpage>1001</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1038/s41436-018-0260-9</pub-id><pub-id pub-id-type="pmid">30232381</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>A</given-names></name><name><surname>Toepfer</surname> <given-names>CN</given-names></name><name><surname>Schmid</surname> <given-names>M</given-names></name><name><surname>Garfinkel</surname> <given-names>AC</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Differentiation and contractile analysis of GFP-Sarcomere reporter hiPSC-Cardiomyocytes</article-title><source>Current Protocols in Human Genetics</source><volume>96</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1002/cphg.53</pub-id><pub-id pub-id-type="pmid">29364522</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>A</given-names></name><name><surname>Toepfer</surname> <given-names>CN</given-names></name><name><surname>Ward</surname> <given-names>T</given-names></name><name><surname>Wasson</surname> <given-names>L</given-names></name><name><surname>Agarwal</surname> <given-names>R</given-names></name><name><surname>Conner</surname> <given-names>DA</given-names></name><name><surname>Hu</surname> <given-names>JH</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>CRISPR/Cas9-Mediated fluorescent tagging of endogenous proteins in human pluripotent stem cells</article-title><source>Current Protocols in Human Genetics</source><volume>96</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1002/cphg.52</pub-id><pub-id pub-id-type="pmid">29364519</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>ZD</given-names></name><name><surname>Lee</surname> <given-names>K</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Amin</surname> <given-names>S</given-names></name><name><surname>Verma</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>QV</given-names></name><name><surname>Zhu</surname> <given-names>Z</given-names></name><name><surname>Soh</surname> <given-names>CL</given-names></name><name><surname>Kumar</surname> <given-names>R</given-names></name><name><surname>Evans</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Huangfu</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome editing in hPSCs reveals GATA6 haploinsufficiency and a genetic interaction with GATA4 in human pancreatic development</article-title><source>Cell Stem Cell</source><volume>20</volume><fpage>675</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2017.01.001</pub-id><pub-id pub-id-type="pmid">28196600</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sifrim</surname> <given-names>A</given-names></name><name><surname>Hitz</surname> <given-names>MP</given-names></name><name><surname>Wilsdon</surname> <given-names>A</given-names></name><name><surname>Breckpot</surname> <given-names>J</given-names></name><name><surname>Turki</surname> <given-names>SH</given-names></name><name><surname>Thienpont</surname> <given-names>B</given-names></name><name><surname>McRae</surname> <given-names>J</given-names></name><name><surname>Fitzgerald</surname> <given-names>TW</given-names></name><name><surname>Singh</surname> <given-names>T</given-names></name><name><surname>Swaminathan</surname> <given-names>GJ</given-names></name><name><surname>Prigmore</surname> <given-names>E</given-names></name><name><surname>Rajan</surname> <given-names>D</given-names></name><name><surname>Abdul-Khaliq</surname> <given-names>H</given-names></name><name><surname>Banka</surname> <given-names>S</given-names></name><name><surname>Bauer</surname> <given-names>UM</given-names></name><name><surname>Bentham</surname> <given-names>J</given-names></name><name><surname>Berger</surname> <given-names>F</given-names></name><name><surname>Bhattacharya</surname> <given-names>S</given-names></name><name><surname>Bu'Lock</surname> <given-names>F</given-names></name><name><surname>Canham</surname> <given-names>N</given-names></name><name><surname>Colgiu</surname> <given-names>IG</given-names></name><name><surname>Cosgrove</surname> <given-names>C</given-names></name><name><surname>Cox</surname> <given-names>H</given-names></name><name><surname>Daehnert</surname> <given-names>I</given-names></name><name><surname>Daly</surname> <given-names>A</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Fryer</surname> <given-names>A</given-names></name><name><surname>Gewillig</surname> <given-names>M</given-names></name><name><surname>Hobson</surname> <given-names>E</given-names></name><name><surname>Hoff</surname> <given-names>K</given-names></name><name><surname>Homfray</surname> <given-names>T</given-names></name><name><surname>Kahlert</surname> <given-names>AK</given-names></name><name><surname>Ketley</surname> <given-names>A</given-names></name><name><surname>Kramer</surname> <given-names>HH</given-names></name><name><surname>Lachlan</surname> <given-names>K</given-names></name><name><surname>Lampe</surname> <given-names>AK</given-names></name><name><surname>Louw</surname> <given-names>JJ</given-names></name><name><surname>Manickara</surname> <given-names>AK</given-names></name><name><surname>Manase</surname> <given-names>D</given-names></name><name><surname>McCarthy</surname> <given-names>KP</given-names></name><name><surname>Metcalfe</surname> <given-names>K</given-names></name><name><surname>Moore</surname> <given-names>C</given-names></name><name><surname>Newbury-Ecob</surname> <given-names>R</given-names></name><name><surname>Omer</surname> <given-names>SO</given-names></name><name><surname>Ouwehand</surname> <given-names>WH</given-names></name><name><surname>Park</surname> <given-names>SM</given-names></name><name><surname>Parker</surname> <given-names>MJ</given-names></name><name><surname>Pickardt</surname> <given-names>T</given-names></name><name><surname>Pollard</surname> <given-names>MO</given-names></name><name><surname>Robert</surname> <given-names>L</given-names></name><name><surname>Roberts</surname> <given-names>DJ</given-names></name><name><surname>Sambrook</surname> <given-names>J</given-names></name><name><surname>Setchfield</surname> <given-names>K</given-names></name><name><surname>Stiller</surname> <given-names>B</given-names></name><name><surname>Thornborough</surname> <given-names>C</given-names></name><name><surname>Toka</surname> <given-names>O</given-names></name><name><surname>Watkins</surname> <given-names>H</given-names></name><name><surname>Williams</surname> <given-names>D</given-names></name><name><surname>Wright</surname> <given-names>M</given-names></name><name><surname>Mital</surname> <given-names>S</given-names></name><name><surname>Daubeney</surname> <given-names>PE</given-names></name><name><surname>Keavney</surname> <given-names>B</given-names></name><name><surname>Goodship</surname> <given-names>J</given-names></name><name><surname>Abu-Sulaiman</surname> <given-names>RM</given-names></name><name><surname>Klaassen</surname> <given-names>S</given-names></name><name><surname>Wright</surname> <given-names>CF</given-names></name><name><surname>Firth</surname> <given-names>HV</given-names></name><name><surname>Barrett</surname> <given-names>JC</given-names></name><name><surname>Devriendt</surname> <given-names>K</given-names></name><name><surname>FitzPatrick</surname> <given-names>DR</given-names></name><name><surname>Brook</surname> <given-names>JD</given-names></name><name><surname>Hurles</surname> <given-names>ME</given-names></name><collab>INTERVAL Study</collab><collab>UK10K Consortium</collab><collab>Deciphering Developmental Disorders Study</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing</article-title><source>Nature Genetics</source><volume>48</volume><fpage>1060</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1038/ng.3627</pub-id><pub-id pub-id-type="pmid">27479907</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simões-Costa</surname> <given-names>M</given-names></name><name><surname>Bronner</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Establishing neural crest identity: a gene regulatory recipe</article-title><source>Development</source><volume>142</volume><fpage>242</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1242/dev.105445</pub-id><pub-id pub-id-type="pmid">25564621</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname> <given-names>D</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A genetic blueprint for cardiac development</article-title><source>Nature</source><volume>407</volume><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/35025190</pub-id><pub-id pub-id-type="pmid">11001064</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname> <given-names>T</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Hoffman</surname> <given-names>P</given-names></name><name><surname>Hafemeister</surname> <given-names>C</given-names></name><name><surname>Papalexi</surname> <given-names>E</given-names></name><name><surname>Mauck</surname> <given-names>WM</given-names></name><name><surname>Hao</surname> <given-names>Y</given-names></name><name><surname>Stoeckius</surname> <given-names>M</given-names></name><name><surname>Smibert</surname> <given-names>P</given-names></name><name><surname>Satija</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive integration of Single-Cell data</article-title><source>Cell</source><volume>177</volume><fpage>1888</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id><pub-id pub-id-type="pmid">31178118</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuelsatz</surname> <given-names>P</given-names></name><name><surname>Keire</surname> <given-names>P</given-names></name><name><surname>Almuly</surname> <given-names>R</given-names></name><name><surname>Yablonka-Reuveni</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A contemporary atlas of the mouse diaphragm: myogenicity, Vascularity, and the Pax3 connection</article-title><source>The Journal of Histochemistry and Cytochemistry</source><volume>60</volume><fpage>638</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1369/0022155412452417</pub-id><pub-id pub-id-type="pmid">22723526</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulahian</surname> <given-names>R</given-names></name><name><surname>Casey</surname> <given-names>F</given-names></name><name><surname>Shen</surname> <given-names>J</given-names></name><name><surname>Qian</surname> <given-names>ZR</given-names></name><name><surname>Shin</surname> <given-names>H</given-names></name><name><surname>Ogino</surname> <given-names>S</given-names></name><name><surname>Weir</surname> <given-names>BA</given-names></name><name><surname>Vazquez</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Bass</surname> <given-names>AJ</given-names></name><name><surname>Chan</surname> <given-names>V</given-names></name><name><surname>Shivdasani</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric Cancer</article-title><source>Oncogene</source><volume>33</volume><fpage>5637</fpage><lpage>5648</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.517</pub-id><pub-id pub-id-type="pmid">24317510</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname> <given-names>JK</given-names></name><name><surname>Mileikovskaia</surname> <given-names>M</given-names></name><name><surname>Koshiba-Takeuchi</surname> <given-names>K</given-names></name><name><surname>Heidt</surname> <given-names>AB</given-names></name><name><surname>Mori</surname> <given-names>AD</given-names></name><name><surname>Arruda</surname> <given-names>EP</given-names></name><name><surname>Gertsenstein</surname> <given-names>M</given-names></name><name><surname>Georges</surname> <given-names>R</given-names></name><name><surname>Davidson</surname> <given-names>L</given-names></name><name><surname>Mo</surname> <given-names>R</given-names></name><name><surname>Hui</surname> <given-names>CC</given-names></name><name><surname>Henkelman</surname> <given-names>RM</given-names></name><name><surname>Nemer</surname> <given-names>M</given-names></name><name><surname>Black</surname> <given-names>BL</given-names></name><name><surname>Nagy</surname> <given-names>A</given-names></name><name><surname>Bruneau</surname> <given-names>BG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Tbx20 dose-dependently regulates transcription factor networks required for mouse heart and motoneuron development</article-title><source>Development</source><volume>132</volume><fpage>2463</fpage><lpage>2474</lpage><pub-id pub-id-type="doi">10.1242/dev.01827</pub-id><pub-id pub-id-type="pmid">15843409</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tischfield</surname> <given-names>MA</given-names></name><name><surname>Bosley</surname> <given-names>TM</given-names></name><name><surname>Salih</surname> <given-names>MA</given-names></name><name><surname>Alorainy</surname> <given-names>IA</given-names></name><name><surname>Sener</surname> <given-names>EC</given-names></name><name><surname>Nester</surname> <given-names>MJ</given-names></name><name><surname>Oystreck</surname> <given-names>DT</given-names></name><name><surname>Chan</surname> <given-names>WM</given-names></name><name><surname>Andrews</surname> <given-names>C</given-names></name><name><surname>Erickson</surname> <given-names>RP</given-names></name><name><surname>Engle</surname> <given-names>EC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Homozygous HOXA1 mutations disrupt human brainstem, inner ear, cardiovascular and cognitive development</article-title><source>Nature Genetics</source><volume>37</volume><fpage>1035</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1038/ng1636</pub-id><pub-id pub-id-type="pmid">16155570</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tvrdik</surname> <given-names>P</given-names></name><name><surname>Capecchi</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Reversal of Hox1 gene subfunctionalization in the mouse</article-title><source>Developmental Cell</source><volume>11</volume><fpage>239</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2006.06.016</pub-id><pub-id pub-id-type="pmid">16890163</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Linde</surname> <given-names>D</given-names></name><name><surname>Konings</surname> <given-names>EE</given-names></name><name><surname>Slager</surname> <given-names>MA</given-names></name><name><surname>Witsenburg</surname> <given-names>M</given-names></name><name><surname>Helbing</surname> <given-names>WA</given-names></name><name><surname>Takkenberg</surname> <given-names>JJ</given-names></name><name><surname>Roos-Hesselink</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis</article-title><source>Journal of the American College of Cardiology</source><volume>58</volume><fpage>2241</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2011.08.025</pub-id><pub-id pub-id-type="pmid">22078432</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Rodriguez</surname> <given-names>RT</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Ghodasara</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Targeting SOX17 in human embryonic stem cells creates unique strategies for isolating and analyzing developing endoderm</article-title><source>Cell Stem Cell</source><volume>8</volume><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2011.01.017</pub-id><pub-id pub-id-type="pmid">21362573</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname> <given-names>CH</given-names></name><name><surname>Kim</surname> <given-names>TW</given-names></name><name><surname>Koh</surname> <given-names>SJ</given-names></name><name><surname>Choi</surname> <given-names>YE</given-names></name><name><surname>Hur</surname> <given-names>J</given-names></name><name><surname>Kwon</surname> <given-names>YW</given-names></name><name><surname>Cho</surname> <given-names>HJ</given-names></name><name><surname>Kim</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>Gata6</italic> in pluripotent stem cells enhance the potential to differentiate into cardiomyocytes</article-title><source>BMB Reports</source><volume>51</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.5483/BMBRep.2018.51.2.176</pub-id><pub-id pub-id-type="pmid">29335067</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>L</given-names></name><name><surname>Bennett</surname> <given-names>JT</given-names></name><name><surname>Wynn</surname> <given-names>J</given-names></name><name><surname>Carvill</surname> <given-names>GL</given-names></name><name><surname>Cheung</surname> <given-names>YH</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Mychaliska</surname> <given-names>GB</given-names></name><name><surname>Azarow</surname> <given-names>KS</given-names></name><name><surname>Crombleholme</surname> <given-names>TM</given-names></name><name><surname>Chung</surname> <given-names>DH</given-names></name><name><surname>Potoka</surname> <given-names>D</given-names></name><name><surname>Warner</surname> <given-names>BW</given-names></name><name><surname>Bucher</surname> <given-names>B</given-names></name><name><surname>Lim</surname> <given-names>FY</given-names></name><name><surname>Pietsch</surname> <given-names>J</given-names></name><name><surname>Stolar</surname> <given-names>C</given-names></name><name><surname>Aspelund</surname> <given-names>G</given-names></name><name><surname>Arkovitz</surname> <given-names>MS</given-names></name><name><surname>Mefford</surname> <given-names>H</given-names></name><name><surname>Chung</surname> <given-names>WK</given-names></name><collab>University of Washington Center for Mendelian Genomics</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Whole exome sequencing identifies de novo mutations in <italic>GATA6</italic> associated with congenital diaphragmatic hernia</article-title><source>Journal of Medical Genetics</source><volume>51</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2013-101989</pub-id><pub-id pub-id-type="pmid">24385578</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>LG</given-names></name><name><surname>He</surname> <given-names>QY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization</article-title><source>Bioinformatics</source><volume>31</volume><fpage>2382</fpage><lpage>2383</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv145</pub-id><pub-id pub-id-type="pmid">25765347</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaffran</surname> <given-names>S</given-names></name><name><surname>Kelly</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>New developments in the second heart field</article-title><source>Differentiation</source><volume>84</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.diff.2012.03.003</pub-id><pub-id pub-id-type="pmid">22521611</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaidi</surname> <given-names>S</given-names></name><name><surname>Brueckner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetics and genomics of congenital heart disease</article-title><source>Circulation Research</source><volume>120</volume><fpage>923</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309140</pub-id><pub-id pub-id-type="pmid">28302740</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaret</surname> <given-names>KS</given-names></name><name><surname>Carroll</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Pioneer transcription factors: establishing competence for gene expression</article-title><source>Genes &amp; Development</source><volume>25</volume><fpage>2227</fpage><lpage>2241</lpage><pub-id pub-id-type="doi">10.1101/gad.176826.111</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>JZ</given-names></name><name><surname>Termglinchan</surname> <given-names>V</given-names></name><name><surname>Shao</surname> <given-names>NY</given-names></name><name><surname>Itzhaki</surname> <given-names>I</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Ma</surname> <given-names>N</given-names></name><name><surname>Tian</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>VY</given-names></name><name><surname>Chang</surname> <given-names>ACY</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Kitani</surname> <given-names>T</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Lam</surname> <given-names>CK</given-names></name><name><surname>Kodo</surname> <given-names>K</given-names></name><name><surname>Sayed</surname> <given-names>N</given-names></name><name><surname>Blau</surname> <given-names>HM</given-names></name><name><surname>Wu</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A human iPSC Double-Reporter system enables purification of cardiac lineage subpopulations with distinct function and drug response profiles</article-title><source>Cell Stem Cell</source><volume>24</volume><fpage>802</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.02.015</pub-id><pub-id pub-id-type="pmid">30880024</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>R</given-names></name><name><surname>Watt</surname> <given-names>AJ</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Luebke-Wheeler</surname> <given-names>J</given-names></name><name><surname>Morrisey</surname> <given-names>EE</given-names></name><name><surname>Duncan</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>GATA6 is essential for embryonic development of the liver but dispensable for early heart formation</article-title><source>Molecular and Cellular Biology</source><volume>25</volume><fpage>2622</fpage><lpage>2631</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.7.2622-2631.2005</pub-id><pub-id pub-id-type="pmid">15767668</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Brown</surname> <given-names>J</given-names></name><name><surname>Kanarek</surname> <given-names>A</given-names></name><name><surname>Rajagopal</surname> <given-names>J</given-names></name><name><surname>Melton</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>In vivo reprogramming of adult pancreatic exocrine cells to β-cells</article-title><source>Nature</source><volume>455</volume><fpage>627</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/nature07314</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.53278.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Morrisey</surname><given-names>Edward E</given-names></name><role>Reviewing Editor</role><aff><institution>University of Pennsylvania</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Duncan</surname><given-names>Stephen</given-names> </name><role>Reviewer</role><aff><institution>Medical University of South Carolina</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Your study clearly defines new roles for <italic>GATA6</italic> in the development of multiple organs. Your study also provides new molecular targets of <italic>GATA6</italic>, generating possible therapeutics targets for cardiac, pancreatic, and diaphragmatic congenital diseases.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;<italic>GATA6</italic> mutations in induced pluripotent stem cells inform developmental mechanisms for heart, pancreas, and diaphragm&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Edward Morrisey as the Senior and Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Stephen Duncan (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As you will see below, all of the reviewers found your study to have significant merit. In your revisions, please pay particular attention to the request for additional data regarding the role of RA signaling and a needed focus on how <italic>GATA6</italic> regulates cardiac differentiation.</p><p><italic>Reviewer #1:</italic></p><p>In this manuscript, Sharma et al. performed extensive RNAseq, scRNAseq and ATACseq on early iPS-derived cardiomyocytes with mutation in exon 4 of <italic>GATA6</italic> or deletion of <italic>GATA6</italic>. In addition, they provide an in depth analysis of <italic>GATA6</italic> mutations and their clinical correlates in published data and in the Pediatric Cardiac Genomics consortium. This resulted in an impressive set of data that will be of major use to field and will help in understanding how <italic>GATA6</italic> mutations cause congenital heart disease and pancreas agenesis, among others. This is a major strength of the manuscript. Perhaps the most interesting and unexpected outcome of this work are the data on the <italic>GATA6<sup>R456G/R456G</sup> </italic>mutant, which was generated based on clinical data and in silico modeling indicating an essential role for this amino acid in <italic>GATA6</italic> transcriptional regulation and its role in heart and pancreas development. These data convincingly show enhanced retinoic acid signaling, which is very interesting. This is also the only weakness of the manuscript. With these exciting data in hand, it would perhaps not be too difficult and translationally highly relevant to examine to what extent inhibiting retinoic acid signaling might correct or at least improve the strong in vitro phenotypes observed. No matter the outcome of such experiments, this would be important information for the field.</p><p><italic>Reviewer #2:</italic></p><p>Review of: <italic>GATA6</italic> Mutations in Induced Pluripotent Stem Cells Inform Developmental Mechanisms for Heart, Pancreas and Diaphragm Malformations – Sharma et al</p><p>The authors present an investigation into the perturbed pathways that manifest in some of the most common pathophysiologies associated with <italic>GATA6</italic> haploinsufficiency. The study uses iPSCs to introduce clinically relevant or loss of function mutations into the <italic>GATA6</italic> gene and study the developmental consequences of these using a cardiac differentiation protocol. This study is well-written and offers an interesting and novel insight into the role <italic>GATA6</italic> plays during cardiac development. There is considerable enthusiasm for the significance of the study, but there is concern that the authors do not provide enough evidence to irrefutably justify a subset of the conclusions that they have drawn. This is particularly true of the findings regarding development of pancreas and diaphragm. It would seem that the manuscript would benefit from a greater focus on the cardiac impact of <italic>GATA6</italic> mutations if supported by additional mechanistic studies.</p><p>1) <italic>GATA6</italic> ChIP-seq analysis is used from previously published datasets from various endoderm populations and cell lines. However, throughout the manuscript the authors refer to GATA binding motifs, common sites which can be bound to varying degrees by GATA1-6. Overlaying the <italic>GATA6</italic> ChIP-seq with the ATAC-seq data will give greater confidence that <italic>GATA6</italic> does indeed bind to the identified GATA motif. A list is said to be provided in the supplementary data; however, it did not appear to be present in the review package. The binding sites should also be identified in the figures showing individual examples of ATAC-seq genome alignment. However, using ChIP-seq data from a different cell type presents its own concerns. Transcription factors, including GATA4, have been shown to have significantly differential binding patterns between different cell types and also have transient binding sites (PMID: 29358654, PMID: 31350899). Therefore drawing conclusions of direct <italic>GATA6</italic> function using the presence of binding motifs or even ChIP-seq derived from different developmental lineages is problematic. Therefore, ChIP-seq data from the cell type/stage of interest, derived previously, or by the authors themselves, would alleviate this concern.</p><p>2) Pancreatic observations are obtained from a cardiac differentiation protocol, using single-cell RNA-seq to identify an endoderm subpopulation. While interesting, these are cells that are being subjected strong exogenous differentiation cues, in a protocol not designed to induce endoderm lineage commitments. Therefore, endodermal differentiation cues are likely being derived via paracrine signaling from mesodermal cells – an undefined variable that may vary between the different <italic>GATA6</italic> genotypes as they follow the developmental trajectories identified. Importantly, <italic>GATA6</italic> haploinsufficiency during pancreatic development using iPSCs has been well-published in the last few years, limiting the novelty of this part of the study (Shi et al., 2017, PMID: 30629940, PMID: 28196690). Indeed, in all three of these studies, FOXA2 has been shown to be down-regulated in <italic>GATA6</italic><sup>+/-</sup> and <sup>-/-</sup> cells compared to <sup>+/+</sup>, whereas it is increased in all but the R456G mutant lines in this study. Given the caveats of this differentiation model, and the conserved findings of the published investigations, it would suggest that the model is not optimized for studying endodermal lineages. Consequently, the observations require follow-up using a specific pancreatic differentiation protocol that more tightly controls the factors required for pancreatic development.</p><p>3) The following points all relate to the major perceived weakness of this study – several points of interest are identified, but no further investigation of them is attempted. This leaves the paper unfocussed. It would seem that this concern could be addressed by focusing on the cardiac elements of the study if the work were supplemented with mechanistic analyses, rather than trying to generate and partially address such a diversity of hypotheses focusing on other lineages. iPSCs represent a fantastic tool for mechanistic studies, so it is disappointing that the model has not been utilized to its full potential.</p><p>4) The authors propose that the <italic>GATA6<sup>R456G/R456G</sup></italic> line has differential transcriptional activity due to altered capacity for DNA binding. The changes in transcriptional and accessibility profile support this hypothesis, but do not confirm it. <italic>GATA6</italic> ChIP-seq should be performed to elucidate the differential <italic>GATA6</italic> binding that occurs in <italic>GATA6</italic><sup>+/+</sup> and <italic>GATA6<sup>R456G</sup></italic> cells. If ChIP-seq is not possible, CHIP-PCR at a number of sites with differential accessibility highlighted throughout the manuscript is required.</p><p>5) Previously derived Hi-C analysis is used to establish potential interactions between distal lncRNA and the HAND2 gene, with GATA-binding motifs found at sites of interaction, and reduced chromatin accessibility observed in the <italic>GATA6</italic> mutant cells. Localized 3-C or equivalent analysis in the <italic>GATA6</italic><sup>+/+</sup> and mutant cells should be used to confirm whether the interactions are perturbed, as hypothesized.</p><p>6) Reduced chromatin accessibility around PLUT1 is identified as a potential cause of the reduced PDX1 expression seen in the endodermal sub-population. The expression of PLUT1 was undetectable using the RNA-seq datasets. Therefore, RT-qPCR should be used to confirm PLUT1 expression is altered in <italic>GATA6</italic> mutant cells. This investigation would preferably be completed in a specific pancreatic differentiation model, for the reasons outlined above.</p><p>7) Increased retinoic acid (RA) signaling is a proposed mechanism by which <italic>GATA6</italic><sup>R456G</sup> mutant cells induce aberrant changes to accessibility changes to induce malformation of the diaphragm. Attempts to rescue this phenotype should be made using RA inhibitors, or phenocopy the observed changes in <italic>GATA6</italic> (<sup>+/+</sup>) cells by supplementing with RA.</p><p><italic>Reviewer #3:</italic></p><p>Overall this is an excellent set of studies from labs that have an established expertise in the definition of the mechanisms that contribute to CHD. These studies clearly link the clinical genotypic and phenotypic data with mechanisms that are further explored using hiPSC-derived CMs. The manuscript is well written with excellent figures and controls (comparing <italic>Gata6</italic> WT, Het, and Variants). The following major issues are intended to help make an already robust study better.</p><p>1) Figure 4: The scRNA-esq analysis focused on a few (limited selected) markers. The authors need to use unbiased pathway analysis to characterize the molecular programs of markers specifically expressed in four clusters identified in D4 and five clusters from D8. A comparison with published scRNA-seq of in vivo heart development (e.g. de Soysa et al., 2019) would be a better way to comprehensively characterize the impact of <italic>Gata6</italic> mutations on the developmental program of second heart field.</p><p>2) Figure 5: The ATAC-seq analysis was also limited on <italic>HAND2</italic> and <italic>SMYD1</italic>. It would be interesting to see the global changes of chromatin accessibility landscape among the four <italic>GATA6</italic> conditions, by using tools such chromVAR.</p><p>As the reviewers were unable to identify CMs in the absence of <italic>Gata6</italic>, is it possible that in this context <italic>Gata6</italic> is functioning as a pioneer factor? Based on the ATAC-seq dataset and the ChIP-seq dataset does <italic>Gata6</italic> bind nucleosomal DNA?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.53278.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>In this manuscript, Sharma et al. performed extensive RNAseq, scRNAseq and ATACseq on early iPS-derived cardiomyocytes with mutation in exon 4 of GATA6 or deletion of GATA6. In addition, they provide an in depth analysis of GATA6 mutations and their clinical correlates in published data and in the Pediatric Cardiac Genomics consortium. This resulted in an impressive set of data that will be of major use to field and will help in understanding how GATA6 mutations cause congenital heart disease and pancreas agenesis, among others. This is a major strength of the manuscript. Perhaps the most interesting and unexpected outcome of this work are the data on the GATA6<sup>R456G/R456G</sup> mutant, which was generated based on clinical data and in silico modeling indicating an essential role for this amino acid in GATA6 transcriptional regulation and its role in heart and pancreas development. These data convincingly show enhanced retinoic acid signaling, which is very interesting. This is also the only weakness of the manuscript. With these exciting data in hand, it would perhaps not be too difficult and translationally highly relevant to examine to what extent inhibiting retinoic acid signaling might correct or at least improve the strong in vitro phenotypes observed. No matter the outcome of such experiments, this would be important information for the field.</p></disp-quote><p>Thank you for this positive impression of our manuscript. We were delayed due to the COVID sequestration but have now performed retinoic acid inhibition experiments in wild type and <italic>GATA6<sup>R456G/R456G</sup></italic> cells at day 4 of differentiation. We treated cells for 24 hours with DMSO or WIN 18446 (Tocris), an inhibitor of ALDH1A2 that catalyzes the synthesis of retinoic acid from retinaldehyde. From RNA-seq analyses of treated WT hiPSCs we observed downregulation of transcripts associated with heart and muscle cell differentiation and increased expression of transcripts associated with endodermal fate specification. By contrast, treated <italic>GATA6<sup>R456G/R456G</sup> </italic>hiPSCs had increased expression of cardiovascular genes, including <italic>HAND2</italic>. Overall, 25% of transcripts in treated <italic>GATA6<sup>R456G/R456G</sup> </italic>hiPSCs were normal or normalized toward levels found in untreated WT cells, including retinoic acid signaling genes (<italic>HOXA1, HOXB1</italic>). These data are included in revised Figure 4—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>Review of: GATA6 Mutations in Induced Pluripotent Stem Cells Inform Developmental Mechanisms for Heart, Pancreas and Diaphragm Malformations – Sharma et al</p><p>The authors present an investigation into the perturbed pathways that manifest in some of the most common pathophysiologies associated with GATA6 haploinsufficiency. The study uses iPSCs to introduce clinically relevant or loss of function mutations into the GATA6 gene and study the developmental consequences of these using a cardiac differentiation protocol. This study is well-written and offers an interesting and novel insight into the role GATA6 plays during cardiac development. There is considerable enthusiasm for the significance of the study, but there is concern that the authors do not provide enough evidence to irrefutably justify a subset of the conclusions that they have drawn. This is particularly true of the findings regarding development of pancreas and diaphragm. It would seem that the manuscript would benefit from a greater focus on the cardiac impact of GATA6 mutations if supported by additional mechanistic studies.</p></disp-quote><p>We appreciate the reviewer’s positive impression of our manuscript. We apologize for the delayed response which reflects both COVID sequestration and requests for many additional experiments that we have performed and incorporated into the revised manuscript. In addition we have substantially reorganized and edited the text to focus on mechanisms for cardiac and extra-cardiac phenotypes.</p><disp-quote content-type="editor-comment"><p>1) GATA6 ChIP-seq analysis is used from previously published datasets from various endoderm populations and cell lines. However, throughout the manuscript the authors refer to GATA binding motifs, common sites which can be bound to varying degrees by GATA1-6. Overlaying the GATA6 ChIP-seq with the ATAC-seq data will give greater confidence that GATA6 does indeed bind to the identified GATA motif. A list is said to be provided in the supplementary data; however, it did not appear to be present in the review package. The binding sites should also be identified in the figures showing individual examples of ATAC-seq genome alignment. However, using ChIP-seq data from a different cell type presents its own concerns. Transcription factors, including GATA4, have been shown to have significantly differential binding patterns between different cell types and also have transient binding sites (PMID: 29358654, PMID: 31350899). Therefore drawing conclusions of direct GATA6 function using the presence of binding motifs or even ChIP-seq derived from different developmental lineages is problematic. Therefore, ChIP-seq data from the cell type/stage of interest, derived previously, or by the authors themselves, would alleviate this concern.</p></disp-quote><p>We agree that ATAC-seq can only provide provisional information regarding transcription factors that regulate gene expression. To more directly define the binding of <italic>GATA6</italic> at GATA motifs we performed <italic>GATA6</italic> ChIP-seq on WT and mutant hiPSCs and re-interpreted ATAC-seq data in the context of these ChIP-seq data. Our new findings are incorporated into the main Figures 5-7 and in supplements associated with each of these figures.</p><p>The integration of ChIP-seq and ATAC-seq data led to several new conclusions:</p><p>We now show that <italic>GATA6</italic> binds GATA motifs at regions of open chromatin (defined by an ATAC-seq peak) as highlighted in the initial manuscript, and that mutant lines have differential expression of the genes. In addition, we demonstrate that <italic>GATA6</italic> also binds closed chromatin that lacks a GATA binding motif. Further, we describe temporal activation of expression for 36% of genes associated with <italic>GATA6</italic> bound to closed chromatin. Notably, many of these genes encode cardiac transcription factors. With these data we deduced that <italic>GATA6</italic> is as a pioneer factor in cardiac development (Figure 5-6).</p><p>Additionally, analyses of <italic>GATA6</italic> ChIP-seq in <italic>GATA6<sup>R456G/R456G</sup></italic> hiPSCs demonstrate reduced binding to GATA motifs in open chromatin as well as over 3-fold increased binding to closed chromatin (without a GATA motif). Based on these data, we conclude that the missense allele has both loss of function (failed binding of the GATA motif) and gain of function (increased binding of closed chromatin, and aberrant gene expression) activities. Together these data help to explain the profound shift in gene expression observed in missense cells.</p><disp-quote content-type="editor-comment"><p>2) Pancreatic observations are obtained from a cardiac differentiation protocol, using single cell RNA-seq to identify an endoderm subpopulation. While interesting, these are cells that are being subjected strong exogenous differentiation cues, in a protocol not designed to induce endoderm lineage commitments. Therefore, endodermal differentiation cues are likely being derived via paracrine signaling from mesodermal cells – an undefined variable that may vary between the different GATA6 genotypes as they follow the developmental trajectories identified. Importantly, GATA6 haploinsufficiency during pancreatic development using iPSCs has been well-published in the last few years, limiting the novelty of this part of the study (Shi et al., 2017, PMID: 30629940, PMID: 28196690). Indeed, in all three of these studies, FOXA2 has been shown to be down-regulated in GATA6 <sup>+/-</sup> and <sup>-/-</sup> cells compared to <sup>+/+</sup>, whereas it is increased in all but the R456G mutant lines in this study. Given the caveats of this differentiation model, and the conserved findings of the published investigations, it would suggest that the model is not optimized for studying endodermal lineages. Consequently, the observations require follow-up using a specific pancreatic differentiation protocol that more tightly controls the factors required for pancreatic development.</p></disp-quote><p>Thank you for these thoughtful comments. We fully agree that considerable information has emerged about the how haploinsufficiency and ablation of <italic>GATA6</italic> perturbs endoderm formation. We also agree with the reviewer that the cardiomyocyte differentiation protocol employed here might result in findings than would not occur with endodermal differentiation in vivo. However, we respectfully disagree that the important and novelty of our data is limited due to these considerations. First, to the best of our knowledge, this is the first demonstration of the profound association between <italic>GATA6</italic> exon 4/5 missense alleles and maldevelopment of the pancreas and diaphragm (Figure 1). Missense mutations in other exons do not cause these phenotypes. Second, our data shows that these missense alleles profoundly activate retinoic acid (RA) signaling, and RA signaling is well recognized (see references in the text) to participate in endoderm formation (e.g., RA activation of <italic>HOXA1/HOXB1</italic>) and diaphragm development (RA activation of <italic>STRA6</italic> and <italic>PAX3</italic>). Together these data provide a molecular explanation for the striking occurrence of these malformations with <italic>GATA6</italic> missense mutations in exon 4/5 – erroneous activation of RA signaling. The inclusion of RA inhibition studies confirms these data. The addition of ChIP-seq data provide further support for these conclusions and provide evidence for widespread epigenetic changes when a mutation both depletes <italic>GATA6</italic> and activates RA signaling, as occurs in the missense lines. Together our data demonstrate the critical importance of the zinc finger-2 binding domain in <italic>GATA6</italic>. Interactions by this domain are essential for cardiac, pancreas and diaphragm development. Finally, understanding why some but not all missense alleles cause these extra-cardiac malformations is clinically important for appropriate recognition of the potential developmental outcomes associated with <italic>GATA6</italic> mutations.</p><disp-quote content-type="editor-comment"><p>3) The following points all relate to the major perceived weakness of this study – several points of interest are identified, but no further investigation of them is attempted. This leaves the paper unfocussed. It would seem that this concern could be addressed by focusing on the cardiac elements of the study if the work were supplemented with mechanistic analyses, rather than trying to generate and partially address such a diversity of hypotheses focusing on other lineages. iPSCs represent a fantastic tool for mechanistic studies, so it is disappointing that the model has not been utilized to its full potential.</p><p>4) The authors propose that the GATA6 <sup>R456G/R456G</sup> line has differential transcriptional activity due to altered capacity for DNA binding. The changes in transcriptional and accessibility profile support this hypothesis, but do not confirm it. GATA6 ChIP-seq should be performed to elucidate the differential GATA6 binding that occurs in GATA6 <sup>+/+</sup> and GATA6 <sup>R456G</sup> cells. If ChIP-seq is not possible, CHIP-PCR at a number of sites with differential accessibility highlighted throughout the manuscript is required.</p></disp-quote><p>Thank you for this important point. In addition to adding new experimental data and interpretation, we substantially revised the manuscript to focus on the epigenetic and transcriptional responses to <italic>GATA6</italic> mutations that result in maldevelopment of the heart, pancreas and diaphragm. As detailed above we now show that GATA6 functions as a cardiac pioneer factor that primes chromatin for subsequent transcriptional activation as well as a traditional transcription factor that regulates gene expression. Heterozygous mutations predominantly perturb its function as a pioneer factor, while homozygous deletion also abrogates functions related to transcriptional activation.</p><p>The comparative GATA6 ChIP-seq data from WT and mutant cells are illustrative of how molecular changes elicit clinical phenotypes. We observe ~17,000 ChIP-seq peaks in <italic>GATA6<sup>+/-</sup></italic> cells, with ~9,000 downregulated and ~6,000 upregulated when compared to WT. The vast majority of associated transcriptional changes indicate decreased gene expression. By contrast there are 21,000 GATA6 ChIP-seq peaks in WT but over 65,000 ChIP-seq peaks in <italic>GATA6<sup>R456G/R456G</sup></italic> cells, with most peaks residing in areas of closed chromatin. These are associated with widespread abnormal transcriptional profiles (increased and decreased in comparison to WT) in <italic>GATA6<sup>R456G/R456G</sup></italic> cells that are not found in <italic>GATA6<sup>+/-</sup></italic> cells. These data has been incorporated into a new set of figures (e.g. Figures 5-6 with associated supplementary figures and files).</p><disp-quote content-type="editor-comment"><p>5) Previously derived Hi-C analysis is used to establish potential interactions between distal lncRNA and the HAND2 gene, with GATA binding motifs found at sites of interaction, and reduced chromatin accessibility observed in the GATA6 mutant cells. Localized 3-C or equivalent analysis in the GATA6 <sup>+/+</sup> and mutant cells should be used to confirm whether the interactions are perturbed, as hypothesized.</p></disp-quote><p>Our GATA6 ChIP-seq results identified some GATA6 binding to regions discovered by Hi-C. However, these reads are not statistically enriched over input, implying indicate that the Hi-C interactions are unlikely to have major regulatory effects on <italic>HAND2</italic> expression. We have therefore removed this data from the revised manuscript. However, the GATA6 ChIP-seq does identify direct GATA6 binding near the <italic>HAND2</italic> locus. As these closed chromatin binding sites are altered in GATA6 mutants, we are still confident that GATA6 participates in regulating <italic>HAND2</italic> gene, through its functions as a pioneer factor (see Figure 7A).</p><disp-quote content-type="editor-comment"><p>6) Reduced chromatin accessibility around PLUT1 is identified as a potential cause of the reduced PDX1 expression seen in the endodermal sub-population. The expression of PLUT1 was undetectable using the RNA-seq datasets. Therefore, RT-qPCR should be used to confirm PLUT1 expression is altered in GATA6 mutant cells. This investigation would preferably be completed in a specific pancreatic differentiation model, for the reasons outlined above.</p></disp-quote><p>While our original hypothesis suggested that PLUT1 was a potential cause of reduced <italic>PDX1</italic> expression at day 4, our GATA6 ChIP-seq analysis found that <italic>GATA6<sup>R456G/R456G</sup></italic> was aberrantly bound to the <italic>PDX1</italic> locus. WT cells do not show GATA6 bound to this locus. At Day 8, GATA6 is bound at the <italic>PDX1</italic> locus, and the ChIP-seq peak is not present in <italic>GATA6<sup>+/-</sup></italic> or <italic>GATA6<sup>-/-</sup></italic> cells, providing a potential PLUT1-independent mechanism of <italic>PDX1</italic> regulation. This data is shown in Figure 7—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>7) Increased retinoic acid (RA) signaling is a proposed mechanism by which GATA6 <sup>R456G</sup> mutant cells induce aberrant changes to accessibility changes to induce malformation of the diaphragm. Attempts to rescue this phenotype should be made using RA inhibitors, or phenocopy the observed changes in GATA6 (<sup>+/+</sup>) cells by supplementing with RA.</p></disp-quote><p>Reviewer 1 also proposed this idea. To address these comments we treated WT and missense cells for 24 hours with DMSO or WIN 18446 (Tocris), an inhibitor of ALDH1A2, which catalyzes the synthesis of retinoic acid from retinaldehyde. From RNA-seq analyses of WT hiPSCs we observed downregulation of transcripts associated with heart and muscle cell differentiation and increase expression of transcripts associated with endodermal fate specification. By contrast, treated <italic>GATA6<sup>R456G/R456G</sup> </italic>hiPSCs had increased expression of cardiovascular genes, including <italic>HAND2</italic>. Overall, 25% of transcripts in treated <italic>GATA6<sup>R456G/R456G</sup> </italic>hiPSCs were normal or normalized toward levels found in untreated WT cells, including retinoic acid signaling genes (<italic>HOXA1, HOXB1</italic>). These data are included in revised Figure 3—figure supplement 2. Please also see Figure 4—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>Overall this is an excellent set of studies from labs that have an established expertise in the definition of the mechanisms that contribute to CHD. These studies clearly link the clinical genotypic and phenotypic data with mechanisms that are further explored using hiPSC-derived CMs. The manuscript is well written with excellent figures and controls (comparing Gata6 WT, Het, and Variants). The following major issues are intended to help make an already robust study better.</p></disp-quote><p>We appreciate the reviewer’s positive impression of our manuscript. We apologize for the delayed response which reflects both COVID sequestration and requests for many additional experiments that we have performed and incorporated into the revised manuscript.</p><disp-quote content-type="editor-comment"><p>1) Figure 4: The scRNA-esq analysis focused on a few (limited selected) markers. The authors need to use unbiased pathway analysis to characterize the molecular programs of markers specifically expressed in four clusters identified in D4 and five clusters from D8. A comparison with published scRNA-seq of in vivo heart development (e.g. de Soysa et al., 2019) would be a better way to comprehensively characterize the impact of Gata6 mutations on the developmental program of second heart field.</p></disp-quote><p>We appreciate this suggestion. We were very aware of the elegant study by de Soysa and colleagues, although we concluded that these mouse data (starting as E7.75) may not be directly relevant to our study that is focused on human development. We also note that there is very limited single cell RNAseq data derived from few captured human cells at gestational age of 7 weeks, which corresponds to E10.5 of mouse hearts (Cui et al., Cell Reports 2019). Our analyses of iPSCs as they begin lineage commitment, identified transcriptional changes by day 4, a time that likely precedes developmental stages characterized in the published single cell mouse and human studies. Additionally as pointed out in the Introduction, GATA6 mutations engineered into mice do not recapitulate phenotypes found in humans. We also hope that the reader recognizes that we did perform unbiased pathway analyses, which led to the Figure 3 in the manuscript. We provide these for the reviewer’s interest in <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>. They are not incorporated into the text due to the considerable information already provided and because of concern by other reviewers that study was insufficiently focused.</p><fig id="sa2fig1"><label>Author response image 1.</label><caption><title>Gene ontology analysis of altered gene networks in day 8 GATA6 LoF and R456G missense cells.</title><p>Gene ontology analysis comparing wild type to GATA6 LoF or R456G cells. Downregulated cardiac gene networks of interest highlighted in red. Upregulated neurodevelopmental gene networks of interest highlighted in blue. Upregulated EMT gene networks of interest highlighted in green. Analysis conducted using gProfileR package in R and uploaded to REVIGO online software (http://revigo.irb.hr/) to generate plots of top 20 GO pathway terms by p value.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53278-resp-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2) Figure 5: The ATAC-seq analysis was also limited on HAND2 and SMYD1. It would be interesting to see the global changes of chromatin accessibility landscape among the four GATA6 conditions, by using tools such chromVAR.</p></disp-quote><p>A broader analysis of the ATAC-seq data is provided in Figure 6—figure supplements 1 and 2. Analysis was performed using HOMER (peak calling and motif analysis) and ChIP-Seeker (genomic localization and annotation). In our opinion, chromVar is a tool that is best suited for single cell ATAC-seq analysis or sparse accessibility data, which does not apply to our dataset.</p><disp-quote content-type="editor-comment"><p>As the reviewers were unable to identify CMs in the absence of Gata6, is it possible that in this context Gata6 is functioning as a pioneer factor? Based on the ATAC-seq dataset and the ChIP-seq dataset does Gata6 bind nucleosomal DNA?</p></disp-quote><p>Thank you for this very important comment. As the reviewer likely recognizes, other GATA proteins have been demonstrated to be pioneer factors. We have now performed extensive analyses of GATA6 ChIP-seq in WT and mutant lines and analyzed these data in the context of ATAC-seq data and temporal expression of genes. We find that in WT cells GATA6 primarily binds closed chromatin (nucleosomal DNA), as only ~10% of the ChIP-seq peaks overlap with ATAC-seq data. We identified temporal increases in gene expression among 36.4% of genes associated with GATA6-bound closed chromatin. Among these differentially expressed genes, 56% encode key cardiac developmental transcription factors, <italic>GATA4, SMYD1, KDR,</italic> and <italic>TBX5</italic> (See Figure 5—figure supplement 1 and Supplementary file 5). Based on these data, we propose that GATA6 is a cardiac development pioneer factor. Moreover, we find that the pioneer factor functions of GATA6 are dysregulated in <italic>GATA6<sup>-/+</sup></italic> cells and even more so in <italic>GATA6<sup>R456G/R456G</sup></italic> cells These new data are incorporated into Figures 5-7.</p></body></sub-article></article>